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ABSTRACT 
Multiple studies have demonstrated that proteases, specifically cathepsin B (Cat B) and 
matrix metalloproteinase-9 (MMP-9) contribute to the remodeling of the extracellular 
matrix (ECM), a hallmark of cardiac hypertrophy (CH). Cat B is activated under acidic 
conditions, a key stimuli of the Na+/H+ exchanger isoform-1 (NHE1). Enhanced NHE1 
expression/activity have also been demonstrated to contribute to the progression of CH. 
Whether NHE1 contributes to the Cat B hypertrophic response remains unclear. NHE1 
activity was stimulated in H9c2 cardiomyoblasts using 10 µM Angiotensin (Ang) II 10 
µM EMD, a NHE1 inhibitor or 10 µM CA-074Me, a Cat B inhibitor and characterized for 
changes in the cell surface area, protein content and atrial natriuretic peptide (ANP) 
mRNA, indices of cardiomyocyte hypertrophy. The localization of Cat B in lysosomes was 
measured using LysoTracker Red dye. The release of Cat B from the intracellular to the 
extracellular space was assessed by measuring Cat B protein expression in the media. 
MMP-9 was also measured in the extracellular space and assessed for its contribution to 
the CAT B hypertrophic response. NHE1 increased the Cat B protein (136.56  9.4% Ang 
II vs. 100% control, 37 kDa and 169.84  14.24% Ang II vs. 100% control, 25 kDa; P<0.05) 
and gene expression (288.11  76.72% Ang II vs. 100% control; P<0.05) and induced 
cardiomyocyte hypertrophy. Furthermore, Cat B protein expression and MMP-9 activity 
were increased in the extracellular space. These effects was regressed upon inhibition of 
NHE1 or Cat B. Our study demonstrates for the first time that Cat B is involved in the 
NHE1 mediated cardiomyocyte hypertrophic response in cooperation with the activation 
of MMP-9.   
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Chapter 1: INTRODUCTION 
1.1 Cardiac Remodeling 
The World Health Organization predicts that by 2030, 23.3 million people can die of 
cardiovascular pathologies with heart failure being the leading cause of death amongst 
them, with the highest increase occurring in the Middle East (1, 2). Over the past three 
decades, the national burden of disease in the population of Qatar has shifted dramatically. 
A recent study has shown that ischemic heart disease is a primary cause of death in Qatar 
(3). Hence, heart failure is a serious health problem that needs to be addressed immediately. 
The key pathophysiological process that ultimately leads to heart failure is cardiac 
remodeling which occurs in response to various cardiovascular pathologies such as cardiac 
hypertrophy (CH), hypertension, and myocardial infarction (MI) if left untreated (4, 5). 
Cardiac remodeling occurs as a result of unbalanced and uncontrolled activity of 
extracellular matrix (ECM) components. Myocardial remodeling is characterized by 
intrinsic changes of the cardiomyocyte and the interstitium such as reorganization of 
myocytes, increased collagen deposition, increased fibrosis, changes in intercellular matrix 
components as well as enlargement of the cardiomyocytes, and is one of the major 
mechanisms that lead the heart to failure (3, 4). Components of the ECM including 
cathepsin (Cat) cysteine proteases and matrix metalloproteinases (MMPs) have a central 
role in ECM remodeling and have been implicated in the development and progression of 
cardiovascular diseases (CVDs). Activation of extracellular proteases and the degradation 
of the ECM, factors which contribute to the remodeling of the ECM, have been associated 
with decreased extracellular pH. A decreased extracellular pH is induced upon Na+/H+ 
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exchanger isoform 1 (NHE1) activation. The cellular interplay of components of the ECM 
and the activation of NHE1 in the setting of cardiac remodeling is the focus of this project.  
CH, one of the hall marks of heart failure, occurs as a result of uncontrolled ECM 
remodeling. Hence, knowledge about its underlying pathological process may hold a key 
to developing therapeutic strategies. 
 
1.2 Cardiac Hypertrophy 
CH is primarily characterized by the enlargement of the cardiomyocytes. It can occur 
as a result of increased work load, hormonal stimuli, and various chronic diseases like 
hypertension (6). CH can be differentiated into physiological or pathological hypertrophy. 
Factors such as increased physical exercise and pregnancy can cause physiological 
hypertrophy of the heart (7, 8). While pathological hypertrophy can be caused by increased 
blood pressure and enhanced neurohormonal activation (9). Pathological hypertrophy, if 
left untreated can eventually lead to heart failure (10). Physiological and pathological 
hypertrophy can be distinguished by the structural and molecular changes occurring. 
Pathological hypertrophy entails the activation of fetal genes such as B-type natriuretic 
peptide (BNP), atrial natriuretic peptide (ANP) and α-actin and β-myosin heavy chain 
(MHC). In addition, an increase in cell size, protein synthesis, and increased fibrosis are 
usually seen in pathological hypertrophy (11, 12). Physiological hypertrophy generally 
does not induce the activation of hypertrophic markers and does not increase the 
accumulation of myocardial collagen (13, 14). Understanding the underlying mechanisms 
of CH is of vital importance in terms of finding potential therapeutic targets.  
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1.2.1 Mechanisms of Cardiac Hypertrophy 
Multiple intracellular signaling pathways regulate CH. Physiological hypertrophy 
causes the activation of protein kinase B (AKT), the insulin like growth factor (IGF), and 
phosphatidylinositol 3 kinase alpha (PI3Kα) pathways (15). While pathological 
hypertrophy could be activated by the activation the calcineurin/nuclear factor of activated 
T-cells (CaN/NFAT), the mitogen activated protein kinases (MAPKs) pathway, cardiac 
specific membrane proteins, integral components of the ECM as well as G-protein coupled 
receptors (GPCRs) and receptor tyrosine kinases have also been implicated in contributing 
to pathological hypertrophy. GPCRs are widely implicated and extensively studied in 
relation to CVDs making them important targets for treatment of cardiac diseases (16). It 
is well known that GPCRs can be activated by binding of agonists such as angiotensin 
(Ang) II, catecholamines and endothelin-1 (ET-1). The activation of GPCRs leads to 
signaling via different G protein sub types (Gαs, Gαq, Gαi, Gβγ) and couples to MAPKs and 
phospholipase C or, in the case of β-adrenergic receptors, to adenyl cyclase and protein 
kinase A (17-19).  It has been demonstrated that over expression of cardiac specific Gαs 
sub unit in transgenic mice induced CH, necrosis and fibrosis upon stimulation with 
catecholamines (20, 21). This suggests that the GPCR signaling pathway plays a major role 
in the cardiac hypertrophic response and could hold the key to its prevention and treatment.  
1.3 Extracellular Matrix  
The ECM is composed of protein such as collagens, elastin, proteoglycans, 
glycoproteins and proteolytic enzymes which are responsible for the maintaining the ECM 
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structure. The ECM functions to form a 3D network amongst the cells and tissues and 
maintains the integrity of the extracellular compartment. The ECM is highly dynamic and 
is constantly undergoing changes in order to facilitate processes such as cell proliferation, 
differentiation, and angiogenesis (22).  
Proteolytic activation and subsequent degradation of the ECM proteins are amongst the 
most important maintenance processes in the ECM. Proteases such as cathepsins and 
MMPs can cause alteration in the ECM structure. This can result in the release of 
biologically active molecules, which influence growth, migration, adhesion, and 
pathological processes (23). MMPs and serine proteases are primarily localized 
extracellularly and are active at neutral pH, hence they were traditionally thought to be the 
main players mediating extracellular proteolysis (24, 25). Whereas, lysosomal proteases 
like the cathepsins were thought to be the majorly involved in intracellular protein turnover 
due to their requirement of an acidic pH for optimal enzyme activity. However, it has been 
recently been discovered that the cathepsins can be released under pathological conditions 
whereby they can remain active in the extracellular compartment and mediate ECM 
degradation (26-30).   
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1.3.1 ECM and the Cardiac System 
The ECM is a critical component of the cardiovascular system. Controlled synthesis 
and degradation of ECM proteins is essential for maintaining the physiological state and 
functioning of the cardiovascular system. However, under pathological conditions such as 
CH and hypertension, there seems to be disturbances in the ECM. These disturbances seem 
to arise due to uncontrolled activities of proteases such as cathepsins and MMPs (31). 
Imbalance in the ECM has been shown to be the cause of many pathological conditions 
such as CVDs, tumors, osteoporosis. Hence, knowing the physiological functioning and 
the pathological changes that occur in the ECM may hold a key to unveiling underlying 
mechanisms. 
Cardiac remodeling occurs primarily as a result of abnormal activation of proteases 
such as cathepsins and MMPs, which results in an imbalance between the synthesis and 
degradation of ECM proteins, resulting in uncontrolled ECM remodeling. (32-35). A study 
reported that the levels of Cat S and K increased significantly with increasing elastolytic 
activity in the tissue extracts from the failing rat myocardium; this response was blunted 
by the broad spectrum cysteine protease inhibitor or a specific inhibitor of Cat S (36, 37). 
Moreover, active Cat S, K, and L have been shown to degrade ECM proteins, including 
laminin (38), fibronectin (39), elastin (40), and collagens (41, 42). Activation of MMPs has 
also been reported to cause left ventricular remodeling in hypertensive heart failure rats 
(43). It is well established that the various isoforms of MMPs can degrade majority of the 
ECM proteins such as various types of collagen, gelatin, fibronectin and laminin (44-47). 
Moreover, cathepsins have the ability to activate pro-MMPs as well. Together, the evidence 
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suggests that enhanced activation of cathepsins and MMPs causes uncontrolled ECM 
remodeling which results in various cardiovascular pathologies (48, 49). Much has already 
been established however, there are still significant void in the understanding their role in 
the failing heart. 
One of the ECM proteins, osteopontin (OPN), was recently shown to be elevated 
during CH (50). Moreover, transgenic mice expressing the cardiac specific active Na+/H+ 
exchanger isoform 1 (NHE1) showed up regulation of OPN mRNA expression in the heart 
compared to the control (50). It was recently shown that the activation or over expression 
of NHE1 causes the up regulation of OPN in cardiomyocytes, which contributes towards 
CH (51, 52). Moreover, NHE1 has been independently shown to induce CH in multiple in 
vitro and in vivo models (53-55) (discussed in section 1.5.3.3).  
Another ECM protein that has been shown to interact with OPN and also to contribute 
towards cardiac remodeling is CD44 (56). It is found on the cell-surface and is involved in 
cell–cell interactions, cell adhesion and migration. The CD44 is responsible for transducing 
intracellular signals in the myocardial cells (57). Moreover, a study reported increased 
expression of CD44 in the hypertrophic heart of aorta-ligated rats. Another study reported 
up regulation of CD44 in infarcted mice hearts as compared to control (58). From the above 
mentioned reports it seems that the components of the ECM play an important role in the 
cardiac remodeling processes, hence the need to further investigate them. Proteases such 
as cathepsins and MMPs have been suggested to play a major role in causing an imbalance 
in the synthesis and degradation of the ECM. Hence, understanding them may hold a key 
to understanding the underlying pathological processes.  
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1.4 Proteases   
Proteases represent about 1 to 4 % of the genes per genome that have been 
sequenced till date and are found in all living forms (59). They are enzymes that are 
involved in the catabolism of unwanted or damaged proteins by hydrolyzing the peptide 
bonds between the amino acids that form them. The hydrolysis of the peptide bonds can be 
executed as a result of the endo and exopeptidase activity of the proteases. Besides their 
primary role in the turnover of proteins, proteases have been identified to play a central 
role in many pathological process that are involved ECM degradation and cardiac 
remodeling. Amongst all proteases, cathepsins and MMPs are amongst the most 
extensively studied proteases in cardiovascular disease and remodeling.  
 
1.4.1 Classification of Proteases  
Proteases have been classified based upon their catalytic site or based upon the 
homology of their amino acids sequences or based upon the homology of their 3D structure 
(60). The human genome consists of about 670 proteases which can be classified based 
upon their site of action into MMPs (constitute about 33% of total proteases), serine (31%), 
cysteine (25%), aspartic (4%), threonine, and glutamic protease (59, 60). Since Cat B 
contains a cysteine residue within its catalytic site, it will fall under the cysteine class of 
proteases. Proteases can also be classified based upon the homology of their amino acid 
sequences to a representative member. Papain, a plant protease, has high homology to Cat 
B. Hence, Cat B is the reference protease of the papain family. Other proteases that are also 
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part of the papain like family are Cat C, F, H, K, L, O, S, V, W, and X (60). Proteases are 
also classified by the homology of their 3D structure and the arrangement of their residue 
on the catalytic site. Cat B belongs to the CA clan because of its specific arrangement with 
the cysteine and histidine residue on the active site (60).  
 
1.4.1.1 Cathepsins 
Cathepsin is derived from the Greek word katehepsin which means to digest. 
Cysteine proteases, discovered in the second half of the 20th century, are the largest sub 
family of cathepsins. They are ubiquitously expressed in all cell types and can be primarily 
found within the lysosomes, where they function to remove damaged and unwanted 
proteins. Cathepsins have been shown to be expressed by cardiomyocytes (36), 
macrophages (61), and immune cells (62).  
 
1.4.1.1.1 Isoforms and Classification of Cathepsins 
Cathepsins comprise of eleven different isoforms (Cat B, C, L, F, H, K, O, S, V, 
W, and X) (27). Cathepsins are further divided into endopeptidases (Cat F, K, L, S, and V) 
or (62) exopeptidases (Cat B, C, H, and X) based upon their cleavages sites (26, 59, 63). 
Most proteases have either endopeptidase or exopeptidase activity. However, Cat B is 
unique in this respect as it has the ability to have both activities along with having peptidyl 
dipeptidase (64) and carboxypeptidase (65) activities (59, 60). This unique property of Cat 
B has been attributed to a particular element in its structure called the occluding loop (66). 
At low pH, the occluding loop covers the active site hence limiting access of its active site 
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to polypeptides. This limits the enzyme’s endopeptidase activity but retains its dipeptidase 
and carboxypeptidase activities (67). At physiological pH, the loop uncovers the active site 
thereby granting more access to the enzyme’s active site. This allows for the endopeptidase 
activity of the enzyme (67). Owing to Cat B’s wide range of peptidase activities, it is 
capable of degrading a wide range of proteins. However, this makes Cat B an even 
dangerous protease under abnormal or pathological condition.  
 
1.4.1.1.2 Structure and Synthesis of Cathepsins 
Cathepsins have been shown to be composed of three general domains, a single 
peptide, pro region, and a catalytic domain (consisting of a heavy chain, and a light chain) 
(27, 68-70) (Figure 1.1). The single peptide, located at the N-terminal of the enzyme, is 
about 10 to 20 amino acids in length and is responsible for the translocation of the enzymes 
into the endoplasmic reticulum (ER) during messenger ribonucleic acid (mRNA) 
translation (28). The cathepsins are then moved to the acidic compartments of lysosomes 
or endosomes, through either the mannose-6-phosphate (M6P) receptor dependent or 
independent pathways. Here, the pro region is cleaved off which results in the liberation of 
the fully active form of the cathepsin which functions to get rid of unwanted proteins (71-
73). Moreover, the acidic compartments give the lysosomal cathepsins the optimum pH for 
their activity. In the case of Cat B, the pro region can be cleaved off by Cat D (aspartic 
protease) and also by self-cleavage (74-76). The pro region of different cathepsins can fall 
anywhere between 36 (Cat X) to 271 (Cat F) amino acids in length. The catalytic domain 
contains the heavy and the light chain of the enzyme and can fall anywhere between 241 
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to 260 amino acids in length. The catalytic domain contains the active site of the enzyme 
which is composed of a cysteine, a histidine, and an asparagine residue (Figure 1.1). The 
pro and the active forms of cathepsins can also be secreted into the extracellular 
compartment by exocytosis (77) (Figure 1.1).  
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Figure 1.1 A model of the cathepsin primary structure and cathepsin maturation 
processes. A. Cathepsins contains a signaling peptide, pro region, heavy chain, and light 
chain. B. The cathepsins maturation process is as follows: The single peptide is removed 
in the ER and disulfide-bound formation, followed by glycosylation of the M6P residue 
and translocation into the Golgi network. The cathepsins are then translocated into the 
endosomes or lysosomes where the pro region is cleaved off. The Ca2+-mediated organelle 
fusion and secretion into extracellular spaces can also take place from the endosomes or 
lysosomes. ER, endoplasmic reticulum; M6P, mannose-6 residue phosphorylation. 
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1.4.1.1.3 Physiological Role of Cathepsins  
Gene ablation studies have revealed that cathepsins have varied physiological 
functions which are important for many biological processes.. Their functions can be at 
most times defined by their tissue localization as in the case of Cat F, S, and K (42, 78-80) 
or general functions such as protein degradation as in the case of ubiquitously expressed 
Cat B, H, and L (81). Cat S and Cat L are involved in the processing of the MHC class II- 
associated invariant chain (78, 82). Cat K, found primarily within the osteoclasts, has been 
shown in multiple studies to be an important player in normal bone remodeling processes 
(78). Cat F, found in the macrophages, has recently been suggested to be an important 
player in the atherosclerotic process and remodeling of the intimal ECM (61). Lysosomal 
Cat, B, H and L, are primarily involved in the bulk protein degradation of proteins with in 
the lysosomes (27, 83, 84). Lysosomal cathepsins are also involved in the conversion of 
pro hormones into their active forms by cleavage of their pro peptides (85). Disturbance in 
the normal functioning of the cathepsins are thought to result in ECM imbalance and in 
turn pathological conditions such as CH (79). Cathepsins also participate in apoptosis, 
although the mechanisms are not yet clearly defined (26).  
 
1.4.1.1.4 Regulation of Cathepsins 
Cathepsins can be regulated in a number of ways, two of the most important being 
through pH changes and inhibition by their endogenous inhibitors, the cystatins (11). 
Cathepsins are primarily regulated by pH when they are localized within the lysosomes. 
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However, once they are released from the lysosomes into the cytosol or into the 
extracellular compartment, their activity is regulated by the cystatins. 
 
Regulation by pH changes 
Generally lysosomal cathepsins are optimally active at slightly acidic pH, around pH 
5,such as those found within the lysosomes (86). The lysosomes are membrane bound 
compartments which contain an acidic microenvironment. The acidic environment is 
created and maintained by pumps that are present on the lysosomal membranes called H+-
ATPase pumps. These pumps pump in H+ using ATP into the lysosomes thereby 
maintaining an acidic environment of about pH 5. This provides the cathepsins with an 
optimal pH to function. The low pH also creates a reducing environments within the 
lysosomes. This prevents the oxidation of the thiol group on the active site of the cathepsins 
and hence prevents their inactivation (59). The pH and redox status-dependent activity of 
cathepsins thus limits their proteolytic efficacy to the endosomal/lysosomal compartment. 
However, it is to be noted that not all cathepsins are optimally active at an acidic pH. Some 
cathepsins like Cat S have the ability to be enzymatically active at neutral pH as well (59). 
The activity of Cat B has been demonstrated to be optimal at an acidic pH value and 
reduced at neutral pH range (87). Cat B also shows changes with respect to its endo and 
exopeptidase activity based upon changes in pH.  Cat B shows dominant endopeptidase 
activity at lower pH values whereas it shows more dominant exopeptidase activity at higher 
pH values. This has been attributed to a special element in its structure called the occluding 
loop. At low pH, the occluding loop covers the active site hence limiting access of its active 
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site to polypeptides. This limits the enzyme’s endopeptidase activity but retains its 
dipeptidase and carboxypeptidase activities (67). At physiological pH, the loop uncovers 
the active site thereby granting more access to the enzyme’s active site. This allows for the 
endopeptidase activity of the enzyme (67). Nonetheless, it has been found that Cat B still 
retains significant proteolytic activity at neutral pH as well (88).  
 
Regulation by endogenous inhibitors 
Cystatins are further divided into intracellular cystatins (stefins A and B), extracellular 
cystatins (cystatin C), and kininogens whereby they control the activity of cathepsins under 
physiological conditions. They are competitive, reversible inhibitors of the cathepsins. 
They inhibit the activity of the cathepsins by binding on to the active site thereby blocking 
access for the substrates and hence inhibiting their activity. The cathepsin inhibitors 
important to maintain the necessary balance during physiological conditions. However, 
imbalance between the cathepsins and cystatin levels has been reported under pathological 
conditions. Decreased levels of cystatin C have been reported in human atherosclerosis and 
aortic aneurysm (89). Moreover, higher cystatin C levels have been associated with having 
a higher risk of CVDs (90). Hence, they are also thought to be important biomarkers for 
CVDs (90).    
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1.4.1.1.5 Cathepsins in Cardiovascular Pathologies  
Cathepsins have been shown to be important mediators in many cardiac 
pathologies. Previous studies have demonstrated that the various isoforms of cathepsins 
mediate cardiac pathologies in varied ways. Some isoforms have been reported to play a 
cardiotoxic role, whereas others have been shown to be cardioprotective.  
 
Cathepsins in Cardiac Hypertrophy and Heart Failure 
Hypertension refers to enhanced arteriole pressure and total peripheral artery 
resistance as a result of hemodynamic overload on the heart. It is well established that high 
blood pressure causes CH, fibrosis, remodeling, and heart failure of Cat S and/or K gene 
and protein levels which were increased in the failing rat myocardium in association with 
hypertension, (36). The levels of the Cat S, B, and K genes have also been shown to be 
increased whereas those of cystatin C showed no significant changes in Dahl salt sensitive 
rats, a model of hypertension (36). Immunohistochemical analysis revealed the expression 
of Cat S and K in the myocardium of hypertensive heart failure rats was markedly increased 
as compared to control rats (36). Furthermore, the elastase assays demonstrated that 
elastase activity of Cat S and K was increased significantly in the tissue extracts from the 
failing rat myocardium. This response was blunted by the broad spectrum cysteine protease 
inhibitor E64 or a specific inhibitor of Cat S (36, 37). Similar to the findings in the rat 
model, the amounts of Cat S and K were found to be increased in the failing myocardium 
of patients with hypertensive heart failure (36). Importantly, Qing Wu et al hypothesized 
that Cat B could also play a prominent role in the pathology of pressure overload-induced 
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cardiac remodeling. Wu et al showed that Cat B levels were upregulated in cardiomyocytes 
in response to hypertrophic stimuli both in vivo and in vitro. Moreover, knockout of Cat B 
attenuated pressure overload-induced CH, fibrosis, dysfunction, and apoptosis. These 
results were further confirmed in in vitro studies utilizing H9c2 cardiomyocytes in which 
hypertrophy was induced by Ang II. Pharmacological Cat B inhibition using CA-074Me 
suppressed the cardiomyocytes hypertrophy by inhibiting the ASK1/JNK pathway. 
Although, the exact mechanism by which Cat B acts in cardiac diseases is still unclear, 
these data indicate an important role of Cat B in the modulation of cardiomyocyte 
hypertrophic response by regulating the signaling pathways involved in cardiac 
remodeling. Taken together, it seem that there is an interplay between the various forms of 
cathepsins in CH and heart failure. More studies are needed to elucidate the role each 
cathepsin plays in the settings of CH and heart failure.  
 
Cathepsins in Cardiomyopathy  
Cardiomyopathy refers to the deterioration of the heart muscles to contract, and 
usually precedes heart failure. In humans, Cat B mRNA and protein levels were shown to 
be greater in dilated cardiomyopathy (DCM) than in control hearts (91). Levels of Cat S, 
B, L, and/or K were also shown to be increased in subjects with dilated and hypertrophic 
cardiomyopathies compared with control subjects (77). Moreover, genetic studies have 
revealed that Cat L deficient mice developed interstitial myocardial fibrosis, a 
characteristic sign of cardiomyopathy (92, 93).Taken together, it seems that various 
cathepsins are involved in the processes that contribute towards cardiomyopathy.  
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Cathepsins in Myocardial Infarction 
Cat B, L, and H were the first to be found in the rat myocardial response to acute 
MI (94). It has been shown that Cat B protein levels and activity in cardiac tissues changed 
in response to injury (95). Another recent study reported an increase in Cat B levels post-
MI in vivo. Cat B inhibition, using specific pharmacologic inhibitor CA-074Me, 
significantly attenuated cardiac dysfunction, and reduced cardiomyocyte size and cardiac 
fibrosis in the experimental MI model, by inhibiting NLRP3 activation (96). It was 
demonstrated in two hypertensive heart failure models (aortic banding and Ang II infusion) 
that the human Cat L transgenic heart shows a decrease in overload-induced CH and 
fibrosis through blocking of the AKT/GSK3 signaling pathway (97). Moreover, in post 
infarction cardiac repair, deletion of Cat L reduced the expression of angiogenic factors 
and decreased revascularization activity (98). Forced expression of Cat L in mature 
endothelial cells considerably enhanced their invasiveness and increased their angiogenic 
capacity in vivo (99). Moreover, it was demonstrated in vivo that myocardial cystatin C is 
increased in mice that develop heart failure in response to hypoxic injury and that this 
increase is associated with local inhibition of Cat B activity and accumulation of collagen 
and fibronectin (100). A study reported that MI induced by left coronary artery ligation in 
wild-type rats caused rapid Cat L activation in myocardium and bone marrow and its 
deficiency contributed to diminished function and adverse remodeling late post-MI (98). 
This study showed that cardiac repair and remodeling benefits from activation of Cat L to 
improve cardiac function after MI injury (98). Moreover, Cat S seems to play a role in 
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cardiac maintenance as well since its deletion exacerbated angiotensin (Ang) II induced 
cardiac inflammation (101). Evidence suggests that cathepsins play diverse role in the CVS 
where some act as cardioprotective while others play a more cardiotoxic role. More studies 
are needed to elucidate the role of the various cathepsins in CVDs.  
 
Cathepsins in Coronary Artery Disease  
ECM remodeling, including collagen and elastin degradation by extracellular 
proteases, contributes to wall stiffening and valve dysfunction (102, 103). Interstitial cells 
in mitral valves express excessive levels of proteolytic enzymes such as Cat S and K, as 
well as MMP-1 and -13, suggesting a role of cathepsins in valve disease (104). Human 
stenotic aortic valves have been shown to contain much greater amounts of Cat S, K, and 
V mRNAs and proteins than controls. (105). Recent ex vivo work demonstrates that cyclic 
stretch increases Cat S, K, and L in porcine valves, accelerating the destruction of aortic 
valvular ECM and the progression of aortic stenosis (106). Cat S deficiency lowered the 
arterial and aortic valve calcification in ApoE deficient mice (106). Taken together, it 
seems that various cathepsins are intimately involved in the pathological processes 
contributing to coronary artery disease.  
 
  
19 
 
Cathepsins in Atherosclerosis 
It was reported that human macrophages secreted active Cat S, B, and L that exhibited 
elastolytic activity (107). More recently, both the gene and protein levels of these enzymes 
were found to be increased in murine diet-induced atherosclerotic plaques (108). Cat S and 
K were the first cysteine cathepsins found to show increased protein levels in human 
atherosclerotic plaque (89, 109). Increased expression of cathepsins occurs in macrophages 
bordering the lipid core adjacent to the fibrous cap and in macrophages and smooth muscle 
cells in the regions surrounding atherosclerotic plaques (110, 111). Evidence suggests that 
cathepsins play a major role in the pathogenesis of atherosclerosis. It has become clear that 
both intracellular and extracellular activities can cause the mechanisms of action of 
cathepsins in atherosclerosis (112). 
 
1.4.1.1.6 Cathepsin and Apoptosis 
Apoptosis is known to be one of the main processes that contribute the heart to failure 
in progression to CH and cardiac remodeling, (113, 114). Apoptosis is a programmed cell 
death mechanism which when activated leads to biochemical and cellular changes which 
eventually terminate in cell death. A family of 14 cysteine proteases called caspases 
primarily regulate apoptosis (115). Apoptosis can occur via an extrinsic pathway or an 
intrinsic one. Extrinsic pathways is mediated by activation of death receptors whereas, the 
intrinsic is mitochondrial- mediated. Both of these pathway can activate caspases which 
then degrade various polypeptides in the cell including major structural elements, 
deoxyribonucleic acid (DNA) repair machinery, and protein kinases (115). The intrinsic 
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pathways plays a major role in cardiomyocyte apoptosis (116), primarily through Bcl-2 
protein and procaspase activation (117, 118). Previous reports have demonstrated that 
increased caspase 3 caused a fall in left ventricular function and inhibition of this caspase 
attenuated ventricular remodeling (119-121). 
The role of cathepsins in pathological apoptosis in cardiac disease has been investigated 
in several animal studies (122). Previous studies have demonstrated that cathepsins are 
essential for cardiomyocyte apoptosis (97). Cat B has been shown to be closely related to 
apoptosis (123, 124). An absence of Cats B and L has been shown to induce neuronal loss 
and brain atrophy (125). Cat B has also been shown to mediate caspase-independent cell 
death in non-small cell lung cancer cells (126). Once Cat B is released from the lysosomes 
into the cytoplasm it may activate or enhance apoptotic pathways (126). Moreover, the 
anti-apoptotic molecules Bcl-2, Bcl-xL, Mcl-1, and XLAP (X-chromosome linked 
inhibitor of apoptosis) are targeted by the lysosomal Cat B and L in several human cancer 
cell lines (127). Taken together, it seems that cathepsins, specifically Cat B, play an 
important role in mediating the processes that lead to apoptosis. 
 
1.4.1.1.7 Cathepsin in the Autophagy-Lysosomal Pathway 
The autophagy–lysosomal system and the ubiquitin–proteasome system (UPS) are the 
primary pathways that maintain the protein turnover in eukaryotic cells (128). In the 
cardiovascular system there is a fine balance between the two systems to maintain 
homeostasis of proteins and organelles (129). The UPS targets small and short lived protein 
by tagging them with ubiquitin (129). In contrast, the autophagy–lysosomal pathway 
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targets long-lived bulky proteins that are defected or damaged under stress (130). 
Dysregulated protein degradation, which can be caused by abnormal or enhanced 
activation of cathepsins and MMPs, has been demonstrated to contribute to cardiac diseases 
(131).  
Cathepsins are important lysosomal protein–processing enzyme and have previously 
been demonstrated to be important in maintaining the autophagy- lysosomal pathway 
activated in response to stress (131). A study reported that the deficiency of lysosomal Cat 
L resulted in the enhanced activation of UPS in the setting of ischemia (131). The final step 
of the autophagy–lysosomal pathway is the fusion of an autophagosome with a functioning 
lysosome. An imbalance of protein homeostasis by dysfunction of this system may lead to 
pathological hypertrophy. Decreased extracellular pH values, which can be caused by an 
overactive NHE1 (132, 133), can cause increased redistribution of lysosomes to the cell 
surface (86, 134, 135) which may be accompanied by fusion with an autophagosome (131). 
Subsequently, the lysosomal contents can be secreted into the ECM as it has been shown 
for Cat B (86). A study demonstrated that extracellular acidic pH values caused the 
redistribution of the lysosome to the cell periphery which paralleled Cat B secretion. 
Interestingly this effect was blocked with several broad and specific NHE inhibitors (136). 
However, the role of the autophagy-lysosomal pathway in mediating the hypertrophic 
cascade in relation to Cat B and NHE1 has not been investigated and remains unknown.   
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1.4.1.1.8 Cathepsin Inhibitors 
The discovery of L-trans-epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) 
was seminal to the development of cathepsin inhibitors. E64 is a non-selective inhibitor of 
the papain family and works by covalently binding onto the active site by alkylation. E64 
is an important inhibitor because it selectively inhibits only the papain family of proteases 
(137). An important derivative of E64 is E64d. E64d is an ethyl ester prodrug, which is 
hydrolyzed in the gut to its active form E64c which is more potent (60). Another derivative 
of E64 is the CA-074 which is a selective Cat B inhibitor. It functions by irreversibly 
binding on to the active site and thereby inhibiting with high potency. CA-074Me was 
developed from CA-074 to have better membrane permeability but it has the ability to 
inhibit both Cat B and L (60). Another cathepsin inhibitor is Leupeptin. Its non-selectively 
inhibits the cysteine and serine proteases by covalently binding on to the active site. Due 
to its decreased selectivity for the papain family of proteases, it is less widely used that E64 
(137). 
 
1.4.1.1.9 Cathepsins Inhibitors in Clinical Trials 
A few cathepsin inhibitors are now being investigated in human trials for several 
diseases such as osteoporosis and rheumatoid arthritis. At least four different Cat K 
inhibitors have entered clinical trials for the treatment of osteoporosis and skeletal 
disorders with excessive bone remodeling. One compound, odanacatib, presently in phase 
III clinical testing (138). Cat S inhibitors, are in preclinical trials for the treatment of 
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rheumatoid arthritis (30). One Cat B inhibitor has completed Phase 1 trials for fatty liver 
disease (139) and another is in late preclinical stage for treating Chagas disease (140). 
However, none of the compounds have been examined for their effect in the setting of 
cardiovascular diseases.  
 
1.4.1.1.10 Clinical Relevance 
A previous study demonstrated that the levels of Cat B protein expression were 
elevated in myocardial samples obtained from DCM patients as compared to controls (91). 
Moreover the gene expression of Cat B was also shown to be elevated (91). Hence, 
inhibition of Cat B might prove to be beneficial for the prevention and treatment of DCM. 
Moreover, a study demonstrated that Cat B knockout mice maintained their health and were 
showed similar effects as normal littermates in behavior, histology, and fertility (141). The 
normal health of mice lacking Cat B implicates that pharmacologic inhibition of Cat B can 
potentially prove to be beneficial in treating cardiomyopathies.  
 
1.4.1.2 Matrix Metalloproteinases 
MMPs are a group of proteolytic enzymes that constitute over 20 isoforms. They 
are primarily responsible for the maintenance of the ECM. Apart from maintenance of the 
ECM they also take part biological processes, such as degradation of connective tissue, 
morphogenesis, angiogenesis, growth, and wound healing (47, 142). MMPs play an 
important role in the pathogenesis of various disorders (143). They are also known to be 
integral to the processes that cause cardiac remodeling and in turn hear failure (144). 
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Therefore, understanding the role of MMPs in physiological and pathological conditions 
is crucial to unveiling the underlying mechanisms of implicated diseases.  
 
1.4.1.2.1 Isoforms and Classification of MMPs  
MMPs have the ability to cleave a wide variety of ECM substrates. Each isoform 
has its own ECM substrate specificity. MMPs are classified into 6 distinct categories based 
upon their target substrates. They are collagenases, stromelysins, matrilysins, gelatinases, 
membrane-type metalloproteinases (MT-MMPs) and other MMPs, namely zinc- and 
calcium-dependent endopeptidases (45) (Figure 1.2). MMP-1, -8, -13 constitute the 
collagenases family and are responsible for breaking down collagen type I, II, and III at 
neutral pH (145, 146). The gelatinases family include MMP-2 and MMP-9. In particular 
gelatinases break down gelatin, denatured collagen, type IV, intact collagen of basal 
membranes and also non-denatured collagens type V, VII, X, XIV, fibronectin, agrecan, 
and elastin (147). Stromelysins include MMP-3, MMP-10, and MMP-11 have a wide 
substrate specificity. They are responsible for the degradation of all non-collagen ECM 
proteins such as proteoglycans, glycoproteins, fibronectin, and laminin (148). 
Macrophagous elastase, MMP-12, have the ability to break down elastin. Gelatinases and 
matrilysins are also able to degrade elastin along with fibronectin, laminin, basal membrane 
collagen, entactin, and chondrotin sulfate (149). MMPs are able to degrade all of the ECM 
components with their combined activities 
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1.4.1.2.2 Structure of MMPs 
MMPs are synthesized as preproenzymes. The pre region is cleaved off to allow for 
the secretion of the inactive proenzymes from the cell into the ECM whereby they are 
activated by other proteases or matrix components. A proenzyme consists of 3 general 
domain: N-terminal propeptide, catalytic domain, and the C-terminal domain (Figure 1.2). 
N-terminal propeptide consists of about 80–90 amino acids containing cysteine residue. 
The cysteine residues interacts with the catalytic zinc through its side chain thiol group, 
and this ensures the inactivity of the proenzyme. Cleavage of a highly conserved sequence 
present in the propeptide region causes activation of the zymogene (150, 151).  
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Figure 1.2 MMP domain structure and classification. A proenzyme molecule is 
organized into the 3 basic structural domains: N-terminal propeptide, catalytic domain, and 
the C-terminal part of the molecule. MMPs are classified into gelatinases, collagenases, 
stromelysins, matrilysins, and membrane type MMPs. MMP, matrix metalloproteinases 
 
1.4.1.2.3 Regulation of MMPs 
The regulation of MMPs activity includes multiple levels of activation of pro 
MMPs, inhibition, secretion of the enzyme molecule and the regulation of gene 
transcription or inhibition of MMPs activity by tissue inhibitors of metalloproteinases 
(TIMPs). The regulation of MMPs activity includes various levels of activation of latent 
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MMPs, inhibition by tissue inhibitors of metalloproteinases (TIMPs), secretion of the 
enzyme molecule and the regulation of gene transcription. 
 
Regulation of MMPs by Cysteine Switch Mechanism  
After propeptide cleavage, the MMP zymogens are changed into active enzymes 
(152). Propeptide contains a conservative sequence, which maintains the enzyme in latent 
form by the chelating action of cysteine residuum to Zn2+ ions at the catalytic site of the 
enzyme (150). Activation of the enzyme is explained by a so called mechanism of a 
cysteine switch (150). The key step is dissociation of zinc-cysteine interaction. 
Extracellular activation of the enzyme includes 2 steps. The first is initial cleavage of the 
MMP propeptide by protease, destabilization of propeptide binding interactions, and break 
of coordination bond of cysteine and Zn2+ ions. The second step is the final cleavage of the 
propeptide that is usually ensured by another MMP. The result is a matured enzyme (153, 
154). 
 
Inhibition of MMPs By Means of TIMPs 
TIMPs are the main endogenous regulators of MMPs in the tissue and are 
responsible for maintaining the balance between the synthesis and degradation of MMPs 
(155). TIMPs molecular weight fall in the range of 21–30 kDa. They constitute four 
isoforms namely, TIMP-1, -2, -3, -4 (155). They bind to MMPs in a ratio 1:1 forming 
binary non-covalent complexes. In this way they protect binding sites for the substrates 
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being split off (155). TIMP-1 forms the complex preferentially with MMP-9, and TIMP-2 
preferentially with MMP-2 (155).  
 
1.4.1.2.4 MMPs in Cardiovascular Pathologies  
Multiple lines of evidence suggest that enhanced levels of vasoactive molecules in 
the circulation can lead to abnormal or enhanced activation of MMPs (144). These 
molecular changes cause the preload and afterload on the heart to increase, thereby causing 
changes in the cardiac structure as a means to compensate for the enhanced workload. 
(144). The compensatory cardiac remodeling is thought to be one of the factors that leads 
the heart to failure. Under normal physiological conditions, the MMPs are responsible for 
the degradation of misfolded and unwanted proteins, thereby maintaining the ECM 
structure (34, 156). However, under pathological conditions there is abnormal activation 
of MMPs, which leads to uncontrolled ECM remodeling and thereby causing various 
cardiac diseases (33, 34). Although, the role of MMPs in cardiac diseases has been 
investigated for quite some time now there are still significant voids in understanding the 
underlying mechanism in the failing heart.  
 
MMPs in Hypertension and Cardiac Hypertrophy 
Hypertension refers to elevated pressure in the arteries and total peripheral resistance 
as a result of hemodynamic overload on the heart. Chronic increase in blood pressure is 
known to be one of the causes of cardiac remodeling, CH, and heart failure (5). Studies 
have demonstrated increase in MMP-9 protein expression and activity whereas, those of 
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TIMP-4 were reduced in Dahl salt-sensitive rats, a model of hypertension (157). In Dahl 
salt-sensitive rats, the gene expression and MMP-2 and MMP-9 activity were shown to be 
upregulated prior to the occurrence of left ventricular dilatation, systolic dysfunction, and 
pulmonary edema. Moreover, angiotensin converting enzyme inhibitors were able to 
abrogate cardiac remodeling suggestion a link between hypertensive hormone stimuli and 
proteolytic remodeling (158). Taken together, the findings from both hypertensive animal 
models and hypertensive patients suggest that various MMPs may be involved in the 
development of hypertensive cardiomyopathies. 
CH, a hallmark of heart failure, involves changes in the ECM structure such as 
increased collagen deposition, increased fibrosis and increase in the cardiomyocyte size 
(159). Increased MMP-9 and MMP-2 expression have also been associated with increased 
heart weight and cardiomyocyte area (160). Serum levels of both MMP-2 and MMP-9 have 
been shown to be increased in patients with hypertrophic cardiomyopathy. However, only 
MMP-9 levels were associated with fibrosis (44). It has also been reported that increased 
MMP-2 and MMP-9 levels in CH are associated with a significant imbalance between 
MMPs and their endogenous inhibitors, TIMPs. Although both extracellular and 
intracellular modifications by proteases are known to occur for obtaining the hypertrophic 
phenotype, mechanisms of these processes are not fully understood.  
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MMPs in Dilated Cardiomyopathy 
DCM is a heart-muscle disorder that can lead to decreased functioning of the heart. 
DCM if left untreated eventually leads to heart failure. DCM is characterized by a distended 
myocardium, increased interstitial fibrosis, chamber dilatation, and impaired functioning 
of the cardiac contractile muscles (161). The activities of various proteases have been 
demonstrated to vary depending upon the stage of the development of DCM. In general, 
MMPs activities appear to contribute to the development of both MI-induced and 
idiopathic DCM as a result of their extensive ECM remodeling capability. MMP-1 and 
MMP-13 are able to degrade both intact collagen and proteoglycans which are further 
altered by MMP-2 and MMP-9 (162). In a DCM rat model, increased levels of MMP-2, 
MMP-9, and TIMP-1 mRNA were reported at 2 weeks post DCM induction (163). 
However, as the DCM progressed into its 6th week, only the level of MMP-2 mRNA were 
seen to be elevated. The results from this study imply that in DCM, MMP-9 plays a role in 
disease progression during the early stages, whereas MMP-2 remains involved for the 
entire developmental stages of DCM (163). Another study reported that MMP-9 protein 
levels were increased, whereas the increase in MMP-2 activity was normalized at the end 
of an 8-week period post-aortic banding (164). Although there are discrepancies in MMPs 
activities between these two experimental models, it is clear that differential activation of 
specific MMPs results in the progression of cardiac remodeling. In addition, increased 
levels of MMP-2, MMP- 3, and MMP-9 have been observed in patients with DCM (165-
167). It is clear from the results that various form of MMPs are involve in the processes of 
cardiac remodeling.  
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1.5 Intracellular pH Regulation in the Heart 
Multiple physiological process such as cell growth, cell volume regulation, 
differentiation, cell migration require strict control of pH in mammalian cells. Many 
enzyme and cell metabolic processes are rely upon the maintenance of optimal pH for their 
functioning.  
 
1.5.1 Mechanisms of Intracellular pH Regulation  
The intracellular pH is maintained by multiple mechanisms. The NHE is the 
primary pH-regulator in mammalian cells (168, 169). The NHE family of pH regulators 
maintains pH by exchanging intracellular protons (H+) for extracellular sodium ion (Na+) 
in a stoichiometric ration of 1:1, hence protecting the cell from acidosis. The NHE family 
is also involved in cell volume regulation by the exchange of H+, Na+, Cl- in and out of 
the cell (169). Thus, NHE is an important role in maintaining the pH and cellular 
metabolism in mammalian cells. In the myocardium, maintenance of the concentration of 
various ions like protons, sodium and calcium is of critical importance for normal 
functions like cell excitability, contractility, and cell volume. Five types of pH regulators 
have been identified in the myocardium, out of which two function to remove protons 
while three of them function to bring in protons and thereby protect the cell against 
acidosis or alkalosis (reviewed in (170, 171) (Figure 1.3). Amongst all the pH regulators, 
the NHE1 plays the most important role in pH maintenance as it is responsible for 50-
60% of the proton efflux (172). Thus, understanding the role of NHE1 is of vital 
importance in order to expose the underlying mechanisms of cardiac diseases. 
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Figure 1.3 Schematic representation of transporters, co-transporters and channels 
that maintain the ionic homeostasis in ventricular cardiomyocytes. Na+ influx is 
controlled by NCX and NHE; Na+ efflux is controlled by NCX and NKA. H+ efflux is 
mediated by MCT, NHE and NBC. H+ influx occurs through MCT, CHE and AE; Ca2+ 
influx is mediated by Ca2+ channels and NCX; Ca2+ efflux is mediated through NCX. 
NHE1, Na+/H+ exchanger isoform 1; NCX, Na+/Ca2+ exchanger; NKA, Na+/K+ ATPase; 
NBC, Na+/HCO3
- cotransporter; MCT, monocarboxylate transporters; AE, anion 
exchanger; CHE, Cl-/OH- exchanger. A version of this figure can be found in (173).   
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1.5.2 NHE Isoforms and Distribution 
Ten isoforms (NHE 1-10) have been identified. NHE isoforms are composed of 12 
transmembrane segments, an N-terminal and C-terminal domains. Each isoform has its 
own tissue specificity, localization, functions, and inhibitors (174). The NHE proteins can 
be localized on the plasma membranes as well as in the intracellular compartments. NHE 
1-5 are primarily localized on the plasma membranes. The NHE1 is the primary isoform 
found in the heart whereas NHE2 and NHE3 are found in the stomach, colon and small 
intestine (9, 175-177). NHE4 is mostly found in the stomach, small intestine, the colon and 
functions similar to NHE (9). NHE5 is thought to maintain the acidity of synaptic vesicles. 
It is primarily expressed in non-epithelial tissue such as the brain (9). NHE6-9 are mostly 
distributed within the intracellular portions of the cell where they function to maintain the 
intracellular pH and ion concentration (178). NHE6 is primarily found in the heart, brain 
and skeletal muscles. NHE7, functions slightly different from other isoform as it is capable 
of exchanging a sodium or a potassium in exchange for protons. It is mainly found in the 
trans-Golgi network (9). NHE8 can be found in skeletal muscles and kidneys whereas NHE 
9 can be found in the endosomes (178). NHE 10, most recently discovered, is found mainly 
in osteoclasts and function in osteoclast differentiation and survival (179). In our study, we 
will be focusing on NHE1, the only cardiac specific isoform of NHEs. 
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1.5.3 Cardiac Specific NHE Isoform 1 
NHE1 is the most extensively studied amongst all NHE isoforms and is the only 
cardiac specific isoform (180, 181). It is located on the plasma membrane and is composed 
of a twelve transmembrane regions. It functions to remove one intracellular proton in 
exchange for one extracellular sodium thereby protecting the cell against acidosis (175). 
The activity of the exchanger is low under physiological conditions. Upon increase in the 
concentration of protons within the cell, the activity rises sharply to maintain the 
intracellular pH of the cell (182).  
 
1.5.3.1 Physiological Role of NHE1  
NHE1 is vital for many physiological processes (reviewed in (174)). NHE1 plays 
an important role in regulating the pH and volume of the cells. Apart from maintaining the 
pH of the cell, NHE1 can also increase the sodium ion concentration within the cell. This 
increase in intracellular pH activates the AE which results in the increase in chloride ions 
within the cell.  This increase in sodium and chloride ions causes influx of water resulting 
in cell swelling (183). NHE1 is also implicated to regulate cell growth, cell volume, 
differentiation, progression, and apoptosis (184-186). Apoptosis causes decrease in cell 
size and drop in intracellular pH. These effects are counteracted by NHE1. However, its 
role in apoptosis is dependent upon the cell type. In both human leukemic cell lines and 
renal proximal tubule, NHE1 seems to protect the cells from apoptosis. In two cytokine-
dependent cell lines, NHE1 causes an increase in intracellular pH that results in apoptosis 
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(187, 188). Moreover, the involvement of NHE1 in apoptosis was demonstrated recently 
in adult rat ventricular myocytes. This study demonstrated that hypoxia/reperfusion 
induced phosphorylation of NHE1 was decreased upon silencing of p90 ribosomal S6 
kinase1 which decreased apoptosis (189). Moreover the inhibition of NHE1 with amiloride 
blocked hypoxia/reperfusion induced apoptosis as well (189). There are still significant 
voids in understanding the role of NHE1 in apoptosis. NHE1 has also been shown to play 
an important role in the maintenance of cytoskeletal structure, focal adhesion and cell 
migration (190, 191) (187, 188). More research is needed to understand the role of NHE1 
in apoptosis. 
 
1.5.3.2 Regulation of NHE1 Activity in the Myocardium 
Regulation of NHE1 mainly occurs through decrease in intracellular pH (192). 
Apart from acidosis, receptor dependent (phosphorylation/dephosphorylation) and receptor 
independent pathways (cofactors or protein-protein interactions) also mediate NHE1 
activity.  
 
Receptor Dependent Regulation of NHE1  
The activity of NHE1 can be stimulated by the activation of a sub type of the G 
protein coupled receptors (GPCRs). The GPCRs is a family of receptors that are composed 
of seven transmembrane helices with an extracellular ligand binding domain and an 
intracellular signal transduction domain (193). The GPCRs constitute four sub types 
namely, Gαs, Gαi, Gαq, and Gα11/12. The NHE1 activity can be stimulated by the activation 
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of Gαq via various agonists. (reviewed in (194)). Gαq can be activated by many hormones 
and paracrine/autocrine stimuli. Moreover, binding of agonist like Phenylephrine (PE) to 
α1- adrenoreceptors (ARs),  Ang II  to Ang II type I receptor type (195), and ET-1 to ET- 
1 receptor (196) can also activate Gαq signaling thus activating downstream signaling 
cascade that are translated into cardiovascular responses (Figure 1.4). Binding of these 
agonist to their receptors raises the intracellular pH threshold for NHE1 activation. 
Regulation of NHE1, mediated by α1-ARs, is the most characterized in the myocardium 
(197). Apart from GPCRs, NHE1 can also be stimulated by thrombin, aldosterone, and 
lysophosphatidic acid (LPA) (198-200).  
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Figure 1.4 G protein coupled receptor regulation of NHE1 in the myocardium. NHE1 
activity is inhibited (-) by activation of Gαs and Gαi coupled receptors (β1-AR, A1 R, 
respectively), upon stimulation with corresponding agonists (β1-agonists and adenosine, 
respectively).NHE1 activity is stimulated (+) by the activation of Gαq coupled receptors 
(AT1R, α1-AR. ET1) upon activation with corresponding agonists (phenylephrine, 
endothelin-1 and angiotensin II). NHE1; sodium proton exchanger isoform 1; AT1R, 
angiotensin II receptor type 1; α1- AR., α1-adrenoreceptors; β1-AR, β1- adrenoreceptors; A1 
R, adenosine receptors. A version of this figure can be found in (173) 
 
  
38 
 
1.5.3.3 Role of NHE1 in Cardiovascular Diseases   
 
NHE1 in Hypertension 
It has been shown that the activity of the NHE1 is increased in essential 
hypertensive patients (201). It has been suggested that hypertension can occur as a result 
of over activation of the NHE1. Over activation of NHE1 can cause the accumulation of 
sodium ions inside the cell. This activates the NCX in reverse mode which expels sodium 
ions outside in exchange for calcium ions, increasing the calcium ion concentration inside 
the cell (202). A study done on rats with hypertension and pathological CH showed that 
the inhibition of NHE1 was able to decrease systolic blood pressure, normalize NHE1 
activity, and regress CH (203).  Despite various studies investigating the role of NHE1 in 
hypertension, its role is still not clear. More studies are needed to clearly define its 
involvement in hypertension. 
 
NHE1 in Cardiac Hypertrophy 
Results from multiple in vivo models of CH have reported an increase in NHE1 mRNA 
expression, protein expression or activity (204, 205). Interestingly, the increase in NHE1 
activity can occur independent of the increase in protein expression (206). Moreover, CH 
was attenuated upon pharmacological inhibition of NHE1 in multiple in vivo models (179). 
CH was abrogated in rabbits subjected to volume and pressure over-load upon NHE1 
inhibition which prevented further development of heart failure (207). In MI models, 
inhibition of NHE1 was demonstrated to decrease right and left ventricular hypertrophy 
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(208-210). Additionally, transgenic mice that were over expressed with active human 
NHE1 have provided further evidence of NHE1 mediated CH, contractile dysfunction and 
heart failure (54). 
 
1.5.3.4 NHE1 Inhibitors 
Many NHE1 inhibitors have been developed over the years. They have been 
developed further in attempts to increase their selectivity to the various isoform of NHE1. 
The first inhibitor to be developed were amiloride derivatives like 5-(N-ethyl-N-isopropyl) 
amiloride (EIPA) and 5-(N, N-Dimethyl) amiloride hydrochloride (DMA) (211). A second 
class of inhibitors were developed with increased selectivity for NHE1. This class included 
N-(2-methyl-4,5-bis(methylsulfonyl)-benzoyl)-guanidine hydrochloride) (EMD87850), 
cariporide (HOE type), eniporide (EMD85131) (212). 
To date, the EMD and HOE type inhibitors have proven to be the most suitable for in vitro 
and in vivo inhibition of NHE1 (209, 213). 
 
1.6 The Cross Talk Between Cat B, MMP-9 and NHE1  
Progression of the heart to failure is primarily caused due to significant remodeling of 
both the ECM and subcellular organelles which occurs as a result of the activation and 
increased proteolytic activities of proteases such as Cat B and MMP-9 (77, 214). Previous 
studies have suggested that the activation of Cat B is induced by the acidification of the 
peri and extracellular space (86, 132, 133).  In various forms of carcinomas, this 
pericellular acidification coincides with the activation of NHE1 (132, 174).  Increased 
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activation of NHE1, similar to Cat B, is involved in the pathogenesis of various cardiac 
diseases including CH (50, 96, 215, 216). Moreover, the activation NHE1 has been shown 
to activate Cat B in various reports. CD44 was shown to interact with NHE1 which created 
an acidic microenvironments leading to Cat B activation in a breast cancer model (132). 
Moreover, NHE1 and Cat B have shown to directly interact with each other and cause ECM 
degradation in another breast cancer model (133). Taken together, the evidence suggests 
that NHE1, through its pH regulating property, might be mediating the activity of Cat B in 
pathological states.  
A previous report has demonstrated that pericellular acidification redistributed the Cat 
B containing lysosomes to the cell surface and caused the secretion of Cat B into the 
extracellular compartment (86). Interestingly, the NHEs have also shown to cause acidic 
extracellular pH which induced lysosome trafficking and subsequent release of Cat B into 
the ECM in a prostate cancer cells (136). Moreover, several broad and specific NHE 
inhibitors were able to inhibit this effect, i.e. redistribution of lysosomes and subsequent 
secretion of Cat B (136). Once into the extracellular compartment, Cat B can degrade the 
ECM (68) and facilitate further ECM degradation by activating other proteases such as 
MMP-9 (217, 218). MMP-9 activity has been shown to be increased in various models of 
heart failure (43, 219) (220, 221). Previous studies have also shown that MMP-9 activity 
was increased in CCL39 cells upon the stimulation of NHE1 with phenylephrine (222). 
Interestingly, Cat B and MMP-9 were shown to directly interact with NHE1 and cause 
ECM degradation in breast cancer (133). Whether NHE1 induces the activation of Cat B, 
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which in turn activates MMP-9 and contributes to cardiomyocyte hypertrophy remains 
unclear. 
 
1.7 Thesis Objectives 
CH is one of the leading causes of death worldwide. Despite advances in cardiovascular 
research, therapeutic targets that regress CH still remain undiscovered. Hence, there is an 
immediate need to further investigate the signaling pathways that mediate CH in order to 
identify potential therapeutic targets. One of the hallmarks of CH is ECM remodeling. 
Multiple studies have shown an important role of proteases, specifically Cat B and MMP-
9, in the degradation of the ECM. Cat B is activated under acidic conditions, such as in 
conditions where there is an overexpression of the cardiac specific pH regulator, NHE1. 
Various studies have shown that enhanced expression and activity of the NHE1 contributes 
towards CH. Moreover, Cat B has also been shown to induce apoptosis and autophagy in 
conditions of heart failure. Increased autophagy can result in the release of Cat B into the 
ECM where it can activate MMP-9 which can result in further ECM degradation. Whether 
there is a link between NHE1 and Cat B-MMP-9 under pH changes in the CH signaling 
pathway remains unknown. The purpose of this study was to (a) Investigate the role of Cat 
B in the NHE1 induced cardiomyocyte hypertrophic response, (b) Investigate the signaling 
pathways that cause the Cat B mediated hypertrophic response, (c) Investigate the role of 
apoptosis and the autophagy-lysosomal pathway in the NHE1 induced cardiomyocyte 
hypertrophic response. Our hypothesis is that activation of NHE1 induces Cat B which in 
turn activates MMP-9, which leads to cardiomyocyte hypertrophy. Furthermore, induction 
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of Cat B also causes the activation of apoptosis and autophagy in the NHE1 induced 
cardiomyocyte hypertrophic response. 
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Chapter 2: MATERIAL AND METHODS 
2.1 Materials 
All chemicals were purchased from BD Biosciences (San Jose, CA), Fisher 
Scientific (Ottawa, ON) or Sigma (St. Louis, MO). The specific NHE1 inhibitor, N-(4,5-
Bis-methansulfony-2-methylbenzoyl) guanidine (EMD 87580/EMD), which was made by 
Harlan Laboratories (Madison, WI) was a generous gift of Dr. N. Beier of Merck KGaA 
(Frankfurt, Germany). The specific Cat B inhibitor, CA-074 methyl ester (CA-074Me) was 
purchased from Santa Cruz Biotechnologies (sc-214647). CA-074Me is a cell permeable 
methyl ester of CA-074. In our study, we aimed to investigate the effect of intracellular Cat 
B inhibition and thus used CA-074Me instead of CA-074 (223). Primary antibodies used 
for Western blotting including rabbit polyclonal Cat B (sc-13985), rabbit polyclonal MMP-
9 (sc-10737) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit 
polyclonal anti-NHE1 (ab67314), anti- OPN (ab8448), anti-α-tubulin (ab4074), and anti-
goat (ab97051) antibodies were from Abcam (Cambridge, MA). Rabbit polyclonal anti-
LC3 A/B (12741) and rabbit monoclonal anti-caspase-3 (9665) were purchased from Cell 
Signaling (Table 2.1).  
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Table 2.1 Primary and secondary antibodies used for Immunoblotting. Primary and 
secondary antibodies were used for the analysis of protein expression of Cat B, NHE1, 
MMP-9, OPN, caspase-3 and LC-3 A/B. Cat B, cathepsin B; NHE1, Na+/H+ exchanger 
isoform-1; MMP-9, matrix metalloproteinase-9; OPN, osteopontin; LC-3 A/B, 
microtubule associated light chain 3 
  
 
Primary 
Antibody 
Company and 
Catalog Number 
 
Band recognition 
sites 
Cat B Rabbit polyclonal 
anti-Cat B 
Santa Cruz 
Biotechnology 
(Santa Cruz, CA); 
sc-13985 
37 (pro Cat B) and 
25 (active Cat B) 
kDa 
MMP-9 Rabbit polyclonal 
anti-MMP-9 
Santa Cruz 
Biotechnology 
(Santa Cruz, CA); 
sc-10737 
92 kDa 
NHE1 Rabbit polyclonal 
anti-NHE1 
Abcam (Cambridge, 
MA); ab67314 
91 kDa 
α-tubulin Rabbit polyclonal 
anti-α-tubulin 
Abcam (Cambridge, 
MA); ab4074 
50 kDa 
LC3 A/B Rabbit 
monoclonal anti-
LC3 A/B 
Cell Signaling; 
12741 
14 (LC3-II) and 16 
(LC3-I) kDa 
Caspase-3 Rabbit 
monoclonal anti-
caspase-3 
Cell Signaling; 9665 17, 19 and 35 kDa 
OPN Rabbit polyclonal 
osteopontin 
Abcam; ab8448 66 and 32 kDa 
Rabbit anti 
goat 
Rabbit polyclonal 
anti-goat 
Abcam; ab97051 - 
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2. 2 In Vitro Studies Using the Rat Embryonic Myoblast Cell Line H9c2 (A summary 
of the experimental model can found in figure 2.3) 
H9c2 myoblasts, a clonal cell line derived from the embryonic BD1X rat heart 
tissue (224) were obtained from European Collections of Cell Cultures (ECACC) and 
cultured in DMEM/F12 1:1 culture media supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin/streptomycin at 37°C in a humidified atmosphere (95% O2-5% 
CO2) (224). The H9c2 cell line shows similar response to hypertrophic parameters as the 
primary cardiomyoblasts and hence can be used as a model for in vitro study of CH (225). 
The H9c2 cell line was originally derived from embryonic rat ventricular tissue, which is 
important as cardiac hypertrophy mainly occurs in the ventricular muscle of the heart (226). 
The well-established Ang II hypertrophic model was used for inducing cardiomyocyte 
hypertrophy and stimulating NHE1 (227). Previous studies have demonstrated that 
exogenous administration of prohypertrophic agents such as Ang II, stimulates NHE-1 
activity (228, 229). 
 
Treatment Workflow 
Upon becoming confluent, cells were seeded at a density of 2.0 × 106 cells per 35mm 
culture dishes and cultured for 48 hours. After 24 hours, the media was changed to serum-
free maintenance medium for a further 24 hours.  
a. General treatment plan: The cells were then treated with Ang II (10 µM) (refer 
section 3.1.3 for use of the specific concentration), Ang II+EMD, Ang II+CA-
074Me, EMD (10 µM) (51), or CA-074Me (10 µM) (216) alone for 24 hours (refer 
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section 3.1.3 for use of the specific time point) (Figure 2.1). Ang II and EMD were 
dissolved in distilled water and CA-074Me was prepared in dimethyl sulfoxide 
(DMSO). The mentioned vehicle, concentration and time point did not have any 
significant effect on the cell viability (Figure 2.2) which was determined using a 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.  
b. Treatment plan for the determination of Ang II concentration to be used: The 
cells were then treated with 1, 10, or 100 µM or 1, 10, or 100 nM Ang II for 24 
hours (refer to section 3.1.3).  
c. Treatment plan for the determination of Ang II time point to be used: The cells 
were then treated with 10 µM Ang II for 0, 3, 6, 12 and 24 hours (refer to section 
3.1.3).  
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Figure 2.1 Schematic representation of treatment groups and parameters analysed. 
For analysis of protein/gene expression, CH markers, signaling pathways (MMP-9, OPN), 
apoptosis and autophagy the H9c2 cardiomyoblasts were treated with Ang II (10 µM), Ang 
II+EMD, Ang II+CA-074Me, EMD (10 µM), or CA-074Me (10 µM) alone for 24 hours. 
CH, cardiac hypertrophy; MMP-9, matrix metalloproteinase-9; Ang II, angiotensin II.  
 
MTT Assay 
Cell viability was measured using MTT assay, based on the MTT conversion into 
formazan crystals using mitochondrial dehydrogenases. Briefly, H9c2 cells were plated at 
a density of 1 x 104 cells/well in 96-well plates. After different treatment for 24 hours, the 
culture medium was replaced with 200 µL of MTT solution (5 mg/mL stock solution in 
PBS, diluted with culture medium to the final concentration 0.5 mg/mL). After 4 hours of 
incubation at 37⁰ C, this solution was removed and the produced formazan was solubilized 
in 150 µL of DMSO. The absorbance was measured at 550 nm using an automated 
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microplate reader. The results confirmed that the mentioned concentrations and the vehicle 
did not have any significant effect on the cell viability (Figure 2.2). 
 
Figure 2.2 Effect of different treatment groups on cell viability. The cell viability was 
tested 24 hours after treatment of H9c2 cardiomyocytes with or without EMD or CA-
074Me by measuring the conversion of MTT to formazan crystals. Data is expressed as % 
of control (non-treated) ±SEM (n=3). 
 
2.2.1 Immunoblotting 
2.2.1.1 Protein Expression in Cell Lysates  
Following treatment, H9c2 cardiomyoblasts were lysed using radio-
immunoprecipitation protein assay (RIPA) buffer as described earlier (55). 
Briefly, cell lysates were centrifuged at 2340 g for 15 minutes at 4°C and 
the supernatant containing the proteins were collected. 
2.2.1.2 Protein Expression in the Culture Media 
Following treatment, the media was collected and centrifuged at 37 g for 5 
minutes at 4°C. The supernatant was collected and stored at -20°C for 
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concentration. The media was concentrated using a vacuum concentrator, 
Concentrator plus (Eppendorf, Germany) at room temperature for 
approximately 8 hours. 
Total amount of protein present was quantified using the DC protein assay kit 
(Biorad) and equal amounts of protein were loaded on the gels. 20-40 µg of proteins were 
resolved on 15% or 9% SDS-PAGE. The membranes were probed with anti-Cat B 
antibody, rabbit polyclonal anti-MMP-9, rabbit polyclonal anti-NHE1, rabbit monoclonal 
anti-LC3 A/B, rabbit monoclonal caspase-3, and rabbit polyclonal OPN (refer table 2.1). 
Anti-α-tubulin was used as a loading control. Immunoreactive proteins were visualized 
using enhanced chemiluminescence (Amersham Biosciences) and imaged using the Alpha 
Innotech FluorChem Imager (Protein Simple, California, USA). 
 
2.2.2 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
RT-PCR was used to analyze Cat B and ANP mRNA expression. RNA was 
extracted using the Trizol RNA extraction protocol. 2 µg of total RNA was reverse 
transcribed into cDNA using High capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) according to the manufacturer’s protocol (Table 2.2). 50-175 ng from the 
cDNA product was used for each PCR reaction. Following an initial denaturation of 3 
minutes at 94°C, the samples were denatured at 94°C for 45 seconds, annealed at 60°C for 
30 seconds and extended at 72°C for 1 minute. After 35 cycles of denaturing, annealing 
and extending, the reaction was terminated at 72°C for 10 minutes for final extension 
(Table 2.3). Cat B cDNA, ANP cDNA, Bcl-2 cDNA and Bax cDNA were amplified 
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separately using the below mentioned primer sequences (Table 2.4). The results were 
normalized using the control β-actin. β-actin is a housekeeping gene and is hence used to 
normalization for sample-specific differences (230). PCR products were then 
electrophoresed on 2% agarose gels stained with ethidium bromide. The mRNA bands 
were imaged using the Alpha Innotech FluorChem Imager (Protein Simple, California, 
USA).  The changes in the mRNA levels were normalized to β-actin and quantified using 
Scion Image software (Scion Corporation, USA). 
Table 2.2 Reverse transcription conditions used for converting RNA to cDNA. RT 
conditions used for the analysis of Cat B and ANP, Bcl-2, Bax mRNA levels. β-actin was 
used as an internal reference gene. RNA, ribonucleic acid; cDNA, complementary 
deoxyribonucleic acid; Cat B, cathepsin B; ANP, atrial natriuretic peptide; mRNA, 
messenger ribonucleic acid; Bcl-2, B-cell lymphoma 2; Bax, Bcl-2 associated X protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Step Temperature 
(⁰C) 
Time 
1 25 10 min 
2 37 2 hours 
3 85 5 min 
4 4 indefinitely 
Lid Temperature 95  
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Table 2.3 Semi-quantitative Reverse Transcription-PCR conditions (RT-PCR). RT-
PCR for the analysis of Cat B and ANP mRNA levels. β-actin was used as an internal 
reference gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.3 Real-Time Polymerase Chain Reaction 
Real-Time PCR was used to analyze Bcl-2 and Bax mRNA expression. RNA was 
extracted using the Trizol RNA extraction protocol. 2 µg of total RNA was reverse 
transcribed into cDNA using High capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) according to the manufacturer’s protocol (Table 2.2). 2 µL from the cDNA 
product was used for each Real-Time PCR reaction. Fast Sybr Green Master Mix (Applied 
Biosystems) was used for Real-Time PCR. Reaction mixture contained 10 µL Sybr Green, 
2 µLof cDNA, 0.5 µL of 20 µM forward and reverse primers (Table 2.4) in a total volume 
of 20 µL. The microtiter plate was then centrifuged at 900 rpm for 5 to 10 seconds. 7500 
fast Real-Time PCR System (Applied Biosystems) was used for the Real-Time PCR run. 
The holding stage conditions were 95⁰C for 20 seconds. Thermal cycling conditions were 
Step Temperature (⁰C) Time  
Initial Denaturation 94 3 min  
Denaturation 94 45 sec 
35 cycles Annealing 60 30 sec 
Extension 72 1 min 
Final Extension 72 10 min  
Hold 4 indefinitely  
 End   
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40 cycles of 3 seconds at 95⁰C and 30 seconds at 60⁰C. The melt curve stage step 1 
conditions were 15 seconds at 95⁰C, followed by 60 seconds at 60⁰C and finally 15 seconds 
at 95⁰C. The results were normalized using the control β-actin. β-actin is a housekeeping 
gene and is hence used to normalization for sample-specific differences (230). The gene 
expression of Bcl-2 and Bax was performed in triplicates. 
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Table 2.4 Synthetic oligonucleotide primer sequences for Semi-quantitative Reverse 
Transcription-PCR. Primer sequences of Cat B, ANP, Bcl-2, Bax mRNA levels. β-actin 
was used as an internal reference gene. 
 
2.2.4 Measurement of Cardiac Hypertrophic Markers  
In order to investigate the role of NHE1 in the cardiomyocyte hypertrophic cascade 
we looked at three cardiomyocyte hypertrophic markers namely, ANP mRNA, protein 
content and cell area. Increase in ANP mRNA and protein synthesis are one of the 
hallmarks of CH and heart failure (231). Additionally, it was shown that treatment with 
hypertrophic agonists like ET-1 and Ang II induced an increase in cell surface area (232, 
233). Thus, their levels were considered as good markers of cardiomyocyte hypertrophy. 
 
Gene Direction Primer Sequence 
β-actin Sense 5′-CGT CAT CCA TGG CGA ACT GG-3′ 
 Antisense 5′-ACG CAG CTC AGT AAC AGT CC-3′ 
CTSB Sense 5′-GGG GGA AAT CTA CAA AAA TG-3′ 
 Antisense 5′-AAA GAC TCC TAT CTG CCT CAC T-3′ 
ANP Sense 5′-CTG CTA GAC CAC CTG GAG GA-3′ 
 Antisense 5′-AAG CTG TTG CAG CCT AGT CC-3′ 
Bcl-2 Sense 5′-AGC GTC AAC AGG GAG ATG TGA-3′ 
 Antisense 5′-GAT GCC GGT TCA GGT ACT CA-3′ 
Bax Sense 5′-CCA AGA AGC TGA GCG AGT GTC TC-3′ 
 Antisense 5′-AGT TGC CAT CAG CAA ACA TGT CA-3′ 
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2.2.4.1 Measurement of Cell Surface Area of H9c2 Cardiomyoblasts 
H9c2 cardiomyoblasts were plated at an average density of 3x104 per 35 mm dish, 
which allowed for clear distinction of cells in DMEM F12 media containing the 10% FBS 
and 1% penicillin/streptomycin and cultured for 24 hours. Upon becoming confluent after 
24 hours, the media was changed to serum-free maintenance medium for a further 24 hours 
and the cells were then treated with Ang II (10 µM), Ang II+EMD (NHE1 inhibitor), Ang 
II+CA-074 Me (Cat B inhibitor), EMD (10 µM), or CA-074Me (10 µM) alone for 24 hours 
by directly adding them to the tissue culture medium. Following treatment, the media was 
aspirated and the cells were washed twice with 1X Phosphate Buffer Saline (PBS). The 
cells were then fixed with 4% formaldehyde and stained with 0.5% crystal violet in 2% 
ethanol. At least 10 cells were averaged from three dishes and represented as one n value. 
The cells were visualized on a bright field through Carl Zeiss AxioCam microscope (Carl 
Zeiss, Germany). Cell area was measured from digitized images using the AxioVision 
Imaging software (Carl Zeiss Microimaging, New York, NY). 
 
2.2.4.2 Measurement of Protein Content of H9c2 Cardiomyoblasts 
Protein content was measured as described previously (234). Briefly, the 
cardiomyoblasts were washed twice in 1X PBS and collected by trypsinization. The total 
number of cardiomyoblasts was calculated using a hemocytometer. Protein concentration 
of cardiomyoblasts lysed in RIPA buffer was measured using the DC protein assay kit 
(Biorad). Protein content was determined by dividing the total amount of protein (μg) by 
the total number of cardiomyoblasts. Results were expressed as % of control (non-treated).  
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2.2.5 Measurement of Cathepsin B Enzyme Activity 
Activity of cathepsin B was determined with cathepsin B activity fluorometric 
assay kit according to the manufacturer’s protocol (abcam) and as previously described 
(235). Briefly, the cells were lysed in 50 µL kit lysis buffer. Cell lysates were centrifuged 
at 12,000 rpm for 15 minutes at 4°C and the supernatant containing the proteins were 
collected. Total amount of protein present in each sample was quantified using the DC 
protein assay kit from Biorad according to the manufacturer’s instructions. 50 µg of 
proteins were used for cathepsin B activity assay. Proteins were incubated at 37C for 1–2 
hours 10 mM Ac-RR-AFC (substrate for cathepsin B). After incubation for 2 hour, 
fluorescence was measured with a fluorescence microplate reader (SpectraMax Geminis 
XS; Molecular Devices, Inc.) at 400/505nm (excitation/emission; for cathepsin B activity). 
 
2.2.6 Measurement of NHE1 Activity 
Cardiomyoblasts plated on coverslips were loaded with 3 µg/mL pH sensitive dye 2,7-
bis(carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM). The 
change in H+ concentration was measured using a PTI Deltascan spectrofluorometer 
(Photon Technology International, Doha, Qatar). The excitation wavelengths were set at 
502.5 nm and 440 nm and the emission wavelength was set at 528.7 nm. The coverslip was 
initially maintained in a pre-warmed solution of Na+-normal buffer (mM (135 NaCl, 5 KCl, 
1.8 CaCl2, 1 MgSO4, 5.5 Glucose, 10 HEPES) at 37°C and was then pulsed with 50 mM 
ammonium chloride to induce an acid load. Following acidification, coverslips were placed 
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in a 37°C pre-warmed solution of Na+-free buffer (135mM N-methyl-D-glucamine, 5mM 
KCl, 1.8mM CaCl2, 1mM MgSO4, 5.5mM Glucose, 10mM HEPES) that was pre-warmed 
to 37°C and adjusted to a pH of 7.3 until a steady acidic pH was reached. The coverslip 
was then placed in Na+-normal buffer to allow the cardiomyoblasts to recover (176). Each 
coverslip was equilibrated in a three-step pH calibration buffer solution containing 135 
mM N-methyl-glucamine and KCl, 10 µM nigericin and adjusted to a pH of 8, 7 or 6 (236). 
The three-step pH calibration was used to generate a standard curve in which the 
fluorescence output measurements were converted into intracellular pH. The initial rate of 
recovery following an induced acid load was measured and used as an indicator of the 
NHE1 activity. 
  
2.2.7 Measurement of MMP-9 Gelatinolytic Activity by Gelatin Zymography in the 
Conditioned Media  
SDS-substrate (gelatin) gels were prepared by adding gelatin (final concentration 
of 0.2%) to a 7.5% standard Laemmli acrylamide polymerization mixture. 80 µg of protein 
from concentrated media samples was loaded per lane without reduction. Following 
electrophoresis, gels were washed thrice for 20 minutes each with 2.5% Triton X-I00. Gels 
were then rinsed and incubated for 24 hours at 37°C in substrate buffer (50 mM Tris HCl, 
0.15 M NaCl, 5 mM CaCl2, and 0.05% NaN3, pH 7.6). After incubation, gels were stained 
for 1 hour in 1% coomassie blue R-250 in acetic acid:methanol:water (1:2.5:6.5), destained 
in the same solvent and scanned for gelatinolytic activity using BioRad gel doc imaging 
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system (Bio-Rad Inc., California, USA). The bands were quantified using Scion Image 
software (Scion Corporation, USA). Bands for MMP-9 were visualized at 92 kDa.  
 
2.2.8 Intracellular Localization of Lysosomes Using LysoTracker Red Dye  
Following treatment, the H9c2 cardiomyoblasts were washed with PBS and 
incubated in DMEM medium containing 75 µM LysoTracker Red DND-99 (Invitrogen), a 
cell-permeable acidotropic probe that selectively labels vacuoles with low internal pH,  for 
30 minutes. The media was removed and the cells were incubated with 1 µM HOECST for 
30 minutes. The cells were then evaluated under a fluorescence microscope 
(OlympusIX70, Olympus Corp.).  
 
2.3 In Vivo Studies Using of Hearts from Transgenic Mice Overexpressing NHE1 (K-
Line); Measurement of Cathepsin B Protein Expression (A summary of the 
experimental model can found in figure 2.3) 
Cat B protein expression in the hearts of transgenic mice overexpressing NHE1 
(53) was investigated by immunohistochemical analysis.  All experimental procedures 
involving mice were in accordance with institutional guidelines on Animal 
Experimentation and were under a French Ministry of Agriculture license and the 
Institutional Animal Care and Use Committee at Qatar University, Doha, Qatar. The 
Institutional Animal Care and Use Committee at Qatar University, Doha, Qatar has 
specifically approved this project  (Research Ethics Approval Number: QU-IACUC 
007/2012). The mice hearts were collected at 13 weeks and were sectioned into 7 µm 
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sections and dried overnight. The sections were then deparaffinized and rehydrated with 
xylene and alcohol, respectively. The antigens were retrieved with Ventana CC1 buffer 
(Tris/EDTA buffer, pH 8) for 4 minutes at 95°C and then for 12 minutes at 100°C. The 
endogenous peroxidase was quenched with 3% H2O2 in PBS for 30 minutes. Heart sections 
were then blocked with Ab Diluent (ROCHE) for at least 20-30 minutes in a moist 
chamber. The sections were then probed with primary antibodies to Cat B at a dilution of 
1:50 in Ab Diluent (ROCHE) for 1 hour at 37⁰C. Biotinylated anti rabbit IgG secondary 
antibody (RPN1004V,GE Healthcare) was then added at a dilution of  1:100 in Ab Diluent 
(ROCHE) for 1 hour at 37°C. Finally, the 3,3-diaminobenzidine (DAB) kit was used. The 
nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI). Images were 
acquired on NIKON microphot-FXA. 
 
2.4 Statistical Analysis 
All values expressed are compared to control (non-treated) ± SEM. Since the data 
represented values with unequal variances that followed a normal distribution, the upaired 
student’s t tests was used to compute differences between groups. A p value of less than 
0.05 was considered a significant difference. * represents p < 0.05 vs. control (non-treated) 
and # represents p < 0.05 vs. Ang II. 
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Figure 2.3 Experimental model used to determine the role of Cat B in NHE1-induced 
cardiomyocyte hypertrophic response. Cardiomyocytes were investigated for Cat B 
protein (in vitro and in vivo) and gene expression. Cardiomyocytes were also characterized 
for parameters of cardiac hypertrophy including ANP mRNA levels, cell surface area, and 
protein content. Hypertrophic signaling pathways were also examined to determine their 
involvement in the NHE1-induced cardiomyocyte hypertrophic response. RT-PCR, reverse 
transcription-polymerase chain reaction; CH, cardiac hypertrophy; Cat B, cathepsin B; 
MMP-9, matrix metalloproteinase-9; ANP, atrial natriuretic peptide; IHC, 
immunohistochemistry.   
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Chapter 3: RESEARCH FINDING 
3.1 In vitro Studies Using the Rat Embryonic Myoblast Cell Line H9c2 to Investigate 
the Cellular Interplay between NHE1 and Cat B 
3.1.1 Measurement of NHE1 Activity Following Stimulation with Ang II 
Previous reports have demonstrated a simultaneous increase in NHE1 activity upon 
stimulation with Ang II in cardiomyocytes (229). In order to determine whether Ang II 
induces NHE1 activity in H9c2 cardiomyocytes, the cells were treated with 100 nM Ang 
II for 18 hours, with or without EMD. NHE1 activity assay revealed that NHE1 activity 
was significantly elevated with 100 nM Ang II concentration at the 18 hour time point, 
which was significantly regressed by EMD (Figure 3.1). 
 
Figure 3.1 Treatment with Ang II induces an increase in NHE1 activity in H9c2 
cardiomyoblasts. Quantification of NHE1 activity in cell lysates of H9c2 cells treated with 
100 nM Ang II, with or without EMD for 18 hours (n=4). *p < 0.05 vs. control.   
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3.1.2 Measurement of NHE1 Protein Expression Following Stimulation with Ang II  
Previous reports have a demonstrated a simultaneous increase in NHE1 activity upon 
stimulation with Ang II in cardiomyocytes but not NHE1 protein expression (229). Our 
previous findings revealed that Ang II induced an increase in NHE1 activity which was 
blocked by EMD (Figure 3.1) In order to determine whether Ang II induces an increase in 
NHE1 protein expression in H9c2 cardiomyocytes as well, the cells were treated with 10 
µM Ang II for 24 hours, with or without EMD or CA-074Me. Immunoblot analysis 
revealed that NHE1 protein expression was not changed with 10 µM Ang II concentration 
at the 24 hour time point (Figure 3.2).  
 
Figure 3.2 Treatment with Ang II causes no change in NHE1 protein expression in 
H9c2 cardiomyoblasts. Representative Western blot of NHE1 protein expression in cell 
lysates of H9c2 cells treated with 10 µM Ang II for 24 hours, with or without EMD or CA-
074Me (n=1). Immunoblotting was against NHE1 (92 kDa) and α-tubulin (50 kDa).  
 
 
3.1.3 Determination of the Optimal Concentration and Time Point At Which Ang II 
Induces Cat B  
Previous studies have shown that Cat B is optimally active under acidic pH (86, 237) 
Similarly, NHE1 is the primary regulator of intracellular pH in cardiomyocytes. Cat B and 
NHE1 have independently been shown to mediate CH (36, 53, 91, 214). Moreover, the 
activation NHE1 has been shown to activate Cat B in a breast cancer model (132). In order 
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to determine whether the activation of NHE1 induces Cat B protein expression in H9c2 
cardiomyoblasts, H9c2 cardiomyoblasts were treated with 1, 10, or 100 µM or 1, 10, or 
100 nM Ang II for 24 hours. Previous reports and our findings (Figure 3.1) have 
demonstrated that NHE1 activity increases upon stimulation with Ang II in ventricular 
myocytes (227), and as such Ang II has been used as experimental model to stimulate 
NHE1 activity. Immunoblot analysis revealed that Cat B protein expression, appearing at 
37 kDa (pro form) and 25 kDa (active form) (238), was significantly elevated following 
stimulation with 10 µM Ang II (180.22  23.40% Ang II vs. 100% control, 25 kDa; and 
180.07  21.97% Ang II vs. 100% control, 37 kDa; P<0.05) (Figure 3.3). Our results 
demonstrate that stimulation of NHE1 with Ang II in H9c2 cardiomyoblasts induces Cat B 
protein expression. 
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A. 
 
B. 
 
Figure 3.3 Stimulation of Na+/H+ exchanger isoform 1 through Ang II elicits a 
concentration-dependent increase in Cat B protein expression in H9c2 
cardiomyoblasts. A. Representative Western blot of Cat B protein expression in cell 
lysates of H9c2 cells treated with 1, 10, or 100 µM or 1, 10, or 100 nM Ang II for 24 hours 
(n=7). Immunoblotting was against Cat B (pro form at 37 kDa and active form at 25 kDa) 
and α-tubulin (50 kDa). B. Quantification of relative levels of Cat B protein expression 
(n=7). Results expressed as % control (α-tubulin) ± %SEM. *p < 0.05 vs. control. 
 
In order to determine the time point at which Ang II maximally induces Cat B 
protein expression in H9c2 cardiomyocytes, the cells were treated with 10 µM Ang II for 
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0, 3, 6, 12 or 24 hours. Immunoblot analysis revealed that Cat B protein expression, 
appearing at 37 kDa (pro form) and 25 kDa (active form), was maximally increased at the 
24 hour time point with 10 µM Ang II concentration (Figure 3.4). It is to be noted here that 
we saw a doublet at the 37 kDa band size which was not observed earlier (Figure 3.1). This 
can be attributed to a longer run time of the Western blot.   
 
Figure 3.4 Stimulation of Na+/H+ exchanger isoform 1 through Ang II elicits a time-
dependent increase in Cat B protein expression in H9c2 cardiomyoblasts 
(representative Western blots). Representative Western blot of Cat B protein expression 
in cell lysates of H9c2 cells treated with 10 µM Ang II for 0, 3, 6, 12 or  24 hours (n=1). 
Immunoblotting was against Cat B (pro form at 37 kDa and active form at 25 kDa) and α-
tubulin (50 kDa).  
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3.1.4 Analysis of Cat B in the Intracellular Compartment  
3.1.4.1 Measurement of Cat B Protein Expression in Cell Lysates 
The activation of NHE1 has been shown to activate Cat B in a breast cancer model 
(132). In order to confirm whether the Ang II stimulated increase in Cat B protein 
expression was in part due to the activation of NHE1 and whether this increase could be 
regressed by NHE1 inhibitor or Cat B inhibitor, the cells were further treated with or 
without EMD or CA-074Me. Immunoblot analysis revealed that Cat B protein expression, 
both pro and active forms, was significantly elevated at the 10 µM Ang II concentration  
(136.56  9.4% Ang II vs. 100% control, 37 kDa and 169.84  14.24% Ang II vs. 100% 
control, 25 kDa; P<0.05) and this increase was regressed significantly by EMD (118.19  
25.5% Ang II+EMD vs. 136.56  9.4% Ang II, 37 kDa and 102.83  14.38% vs. 169.84  
14.24% Ang II, 25 kDa; P<0.05) or CA-074Me  (90.96  13.52% Ang II+CA-074Me vs. 
136.56  9.4% Ang II, 37 kDa and 71.79  7.53% vs. 169.84  14.24% Ang II, 25 kDa; 
P<0.05) (Figure 3.5). 
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A. 
 
B. 
 
Figure 3.5 Stimulation of the Na+/H+ exchanger isoform 1 elicits an increase in Cat B 
protein expression in H9c2 cardiomyoblasts. A. Representative Western blot of Cat B 
protein expression in cell lysates of H9c2 cells treated with Ang II, with or without EMD 
and CA-074Me for 24 hours (n=6-7). Immunoblotting was against Cat B (pro form at 37 
kDa and active form at 25 kDa) and α-tubulin (50 kDa). B. Quantification of relative levels 
of Cat B protein expression (n=6-7). Results expressed as % of control (α-tubulin) ± 
%SEM. *p < 0.05 vs. control, # p < 0.05 vs. Ang II  
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3.1.4.2 Measurement of Cat B mRNA Expression 
Our previous findings revealed an increase in Cat B protein expression in the cell 
lysates upon stimulation of NHE1 with Ang II (Figure 3.5). The increase in protein 
expression could possibly be as a result of transcriptional changes within the cell. Hence, 
we stimulated NHE1 using Ang II and looked at its effect on Cat B gene expression by RT-
PCR analysis. RT-PCR analysis revealed that Cat B gene expression was significantly 
elevated at the 10 µM Ang II concentration (288.11  76.72% Ang II vs. 100% control; 
P<0.05) and this increase was regressed significantly by EMD (161.77  37.14% Ang 
II+EMD vs. 288.11  76.72% Ang II; P<0.05) or CA-074Me (197.49  48.82% Ang 
II+CA-074Me vs. 288.11  76.72% Ang II; P<0.05) (Figure 3.6). 
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A. 
 
B. 
 
Figure 3.6 Stimulation of the Na+/H+ exchanger isoform 1 elicits an increase in Cat B 
gene expression in H9c2 cardiomyoblasts. A. Representative DNA gel of Cat B mRNA 
expression in H9c2 cardiomyocytes treated with Ang II, with or without EMD and CA-
074Me for 24 hours (n=7). cDNA amplification was against Cat B and β-actin. B. 
Quantification of Cat B mRNA expression in H9c2 cardiomyocytes normalized to β-actin 
(n=7). Results expressed as % of control (β-actin)  %SEM. *p < 0.05 vs. control, # p < 
0.05 vs. Ang II. 
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3.1.4.3 Measurement of Cat B Activity Assay 
Our previous findings showed that stimulation of NHE1 using Ang II increased the 
Cat B protein and gene expression significantly (Figures 3.5 and 3.6). Hence, we wanted 
to further investigate the effect of NHE1 stimulation on the activity of Cat B. In order to 
determine whether Ang II induces Cat B activity in H9c2 cardiomyocytes, the cells were 
treated with Ang II, with or without EMD and CA-074Me for 24 hours. Cat B activity 
assay revealed that Cat B activity was not changed due to Ang II treatment in the cell 
lysates (Figure 3.7). Analysis of Cat B activity in the conditioned media also revealed no 
changes in Cat B activity upon activation of NHE1 using Ang II (Figure 3.8). Previous 
studies have shown that Cat B is optimally active at an acidic pH value (132, 237). It is to 
be noted that the culture media utilized for our in vitro model contained buffers to maintain 
the pH. The buffers efficiently maintained the pH of the culture media at a neutral value 
(approximately pH 7.4) which may have prevented the activation of Cat B and hence an 
inability to see any changes in it. Moreover, it is also possible that the assay was not 
sensitive enough to detect the activity of Cat B as we did not see any changes in enzyme 
activity in the positive control as well (data not shown).  
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Figure 3.7 Stimulation of the Na+/H+ exchanger isoform 1 does not elicits an increase 
in Cat B enzyme activity in H9c2 cardiomyoblasts. Quantification of Cat B activity in 
cell lysates of H9c2 cells treated with Ang II, with or without EMD and CA-074Me for 24 
hours (n=4). Results expressed as % control (non-treated) ± %SEM.  
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Figure 3.8 Stimulation of the Na+/H+ exchanger isoform 1 does not elicits an increase 
in Cat B enzyme activity in conditioned media from H9c2 cardiomyoblasts. 
Quantification of Cat B activity in conditioned media from H9c2 cells treated with Ang II, 
with or without EMD and CA-074Me for 24 hours (n=3). Results expressed as % control 
(non-treated) ± %SEM.  
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3.1.5 Characterization of Cat B and NHE1 in the NHE1 Induced Hypertrophic 
Response by Measurement of Cardiac Hypertrophic markers 
Although Cat B and NHE1 have independently been shown to mediate CH (36, 53, 91, 
214), whether Cat B contributes to the hypertrophic response induced by the elevated 
NHE1 activity remains unclear. In order to investigate the role of NHE1 in the 
cardiomyocyte hypertrophic cascade we looked at three cardiomyocyte hypertrophic 
markers namely, ANP mRNA, cell area and protein content. Increase in ANP mRNA and 
protein synthesis are one of the hallmarks of CH and heart failure (231). Additionally, it 
was shown that treatment with hypertrophic agonists like ET-1 and Ang II induced an 
increase in cell surface area (232, 233). Thus, their levels were considered as good markers 
of cardiomyocyte hypertrophy. 
 
3.1.5.1 Measurement of ANP mRNA 
H9c2 cardiomyoblasts stimulated with 10 µM Ang II induced a significant increase 
in ANP mRNA (393.43  66.29% Ang II vs. 100% control; P< 0.05) (Figure 3.9). ANP 
mRNA expression (59.40  12.24 % Ang II+EMD vs. 393.43  66.29% Ang II; P< 0.05) 
(Figure 3.9) was significantly regressed upon treatment with EMD. 
To further confirm the role of Cat B in the NHE1 mediated hypertrophic phenotype, 
H9c2 cardiomyoblasts stimulated with 10 µM Ang II were pre-treated with CA-074Me. 
The inhibition of Cat B in cardiomyoblasts expressing active NHE1 was reversed as 
indicated by the significant reduction in ANP mRNA expression (62.44  13.85% Ang 
II+CA-074Me vs. 393.43  66.29% Ang II; P< 0.05) (Figure 3.9).    
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A. 
 
B. 
 
Figure 3.9 Cat B contributes to Na+/H+ exchanger isoform 1 -induced cardiomyocyte-
hypertrophy in H9c2 cardiomyoblasts. A. Representative DNA gel of ANP mRNA 
expression in H9c2 cardiomyocytes treated with Ang II, with or without EMD and CA-
074Me for 24 hours (n=7). cDNA amplification was against ANP mRNA and β-actin. B. 
Quantification of ANP mRNA expression in H9c2 cardiomyocytes normalized to β-actin 
(n=7). Results expressed as % of control (β-actin)  %SEM. *p < 0.05 vs. control, # p < 
0.05 vs. Ang II.  
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3.1.5.2 Measurement of Cell Area 
H9c2 cardiomyoblasts stimulated with 10 µM Ang II induced a significant increase 
in cell surface area (145.9  8.24% vs. 100% control; P< 0.05) (Figure 3.10). Cell surface 
area (105.311.88% Ang II+EMD vs. 145.9  8.24% Ang II; P< 0.05) (Figure 3.10) was 
significantly regressed upon treatment with EMD.  
To further confirm the role of Cat B in the NHE1 mediated hypertrophic phenotype, 
H9c2 cardiomyoblasts stimulated with 10 µM Ang II were pre-treated with CA-074Me. 
The inhibition of Cat B in cardiomyoblasts expressing active NHE1 was reversed as 
indicated by the significant reduction in cell surface area (97.35  9.08% Ang II+CA-
074Me vs. 145.9  8.24% Ang II; P< 0.05) (Figure 3.10)  
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A.  
 
B. 
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C. 
 
Figure 3.10 Cat B contributes to Na+/H+ exchanger isoform 1 -induced 
cardiomyocyte-hypertrophy in H9c2 cardiomyoblasts. A. Representative crystal violet 
stained microscopy images of H9c2 cardiomyocytes treated with Ang II, with or without 
EMD and CA-074Me for 24 hours (n=4) using bright field Carl Zeiss AxioCam at a 
magnification of 20x. B. Images captured at 20x magnification were zoomed to visualize 
a single H9c2 cardiomyoblast for better comparison between groups. C. Cell surface area 
of at least 30-40 H9c2 cardiomyocytes from 3-4 individual dishes were measured (n=4). 
Results expressed as % of control (non-treated) ± %SEM. *p < 0.05 vs. control, # p < 0.05 
vs. Ang II.  
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3.1.5.3 Measurement of Protein Content 
H9c2 cardiomyoblasts stimulated with 10 µM Ang II induced a significant increase 
in total protein content (154.04  17.79% Ang II vs. 100% control; P< 0.05) (Figure 3.11). 
Total protein content (96.73 ± 9.58% Ang II+EMD vs. 154.04  17.79% Ang II; P< 0.05) 
(Figure 3.11) was significantly regressed upon treatment with EMD. 
To further confirm the role of Cat B in the NHE1 mediated hypertrophic phenotype, 
H9c2 cardiomyoblasts stimulated with 10 µM Ang II were pre-treated with CA-074Me. 
The inhibition of Cat B in cardiomyoblasts expressing active NHE1 was reversed as 
indicated by the significant reduction in total protein content (110.99 ± 13.24% Ang 
II+CA-074Me vs. 154.04  17.79% Ang II; P< 0.05) (Figure 3.11).  
Our findings reveal for the first time that NHE1-induced Cat B expression 
contributes to the hypertrophic response in cardiomyoblasts and that blockage of this effect 
prevents the NHE1.  
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Figure 3.11 Cat B contributes to Na+/H+ exchanger isoform 1 induced cardiomyocyte 
hypertrophy in H9c2 cardiomyoblasts (protein content). Protein content of H9c2 
cardiomyocytes expressed as mg/10 x 106 cell. D. Representative crystal violet stained 
microscopy images of H9c2 cardiomyocytes treated with Ang II, with or without EMD and 
CA-074Me for 24 hours (n=4). Results expressed as % of control (non-treated) ± %SEM. 
*p < 0.05 vs. control, # p < 0.05 vs. Ang II. 
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3.1.6 Translocation of Cat B from the Intracellular to the Extracellular Compartment 
3.1.6.1 Intracellular Localization of Lysosomes Using LysoTracker Red Dye 
Cat B is localized primarily within the acidic environment of the lysosomes, where 
they are optimally active and functional to degrade unwanted and damaged proteins (77). 
The loss of integrity of the lysosomes can cause the release of the Cat B proteases into the 
cytosol or into the extracellular compartment (86). Previous studies have reported an 
increase in lysosomal cathepsin protease activity in tissue samples from disease and failing 
human hearts. Therefore, we aimed to determine the intracellular localization and 
morphology of lysosomes using the acidotropic probe LysoTracker Red in H9c2 
cardiomyoblasts following stimulation with NHE1. H9c2 cardiomyoblasts were stimulated 
with 10 µM Ang II resulted in a dispersion of the lysosomes as compared to control (Figure 
3.12). Inhibition of NHE1 or Cat B showed a more intact structure of the lysosomes (Figure 
3.12).  
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Figure 3.12 Stimulation of the Na+/H+ exchanger isoform 1 causes the loss of lysosomal 
integrity in H9c2 cardiomyoblasts which is protected by Cat B inhibition. 
Representative images of H9c2 cells treated with Ang II, with or without EMD and CA-
074Me for 24 hours using fluorescent microscope OlympusIX70 at 20x magnification 
(n=3). The cells were stained with Lysotracker Red dye.  
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3.1.6.2 Measurement of LC3-II Protein Expression in Cell Lysates  
Our previous findings revealed an increase in dispersion of lysosomes upon 
stimulation of NHE1 and this effect seemed to be protected by the inhibition of Cat B or 
NHE1 (Figure 3.12). Cathespins have previously been demonstrated to be important in 
maintaining the autophagy- lysosomal pathway activated in response to stress (131). 
Previous studies have revealed that autophagy plays an important role in the pathogenesis 
of CVDs (239).  Moreover, NHE1 has also been implicated to promote autophagy (240). 
Microtubule‑associated protein light chain 3-II (LC3-II) is widely used to monitor 
autophagy. The amount of LC3‑II is correlated with the number of autophagosomes (130, 
241), which have been shown to cause the release of the Cat B proteases into the cytosol 
or into the extracellular compartment (59). The levels of LC3-II protein was measured by 
immunoblot analysis in H9c2 cardiomyoblasts treated with 10 µM Ang II, with or without 
the NHE1 or Cat B inhibitors. Our results revealed that LC3-II protein expression, 
appearing at 14 kDa, was significantly elevated following stimulation with 10 µM Ang II 
(204.38  49.83% Ang II vs. 100% control; P<0.05) (Figure 3.13). This effect that was 
significantly regressed upon treatment with EMD (101.35  16.32% Ang II+EMD vs. 
204.38  49.83% Ang II.; P<0.05) (Figure 3.13) or CA-074Me (91.79  22.59% Ang 
II+CA-074Me vs. 204.38  49.83%Ang II.; P<0.05) (Figure 3.13). Our results demonstrate 
that stimulation of NHE1 in H9c2 cardiomyoblasts with Ang II induces a significant 
increase in the autophagic marker LC3-II and this effect is regressed by inhibition of NHE1 
or Cat B. 
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A. 
 
B. 
 
 
Figure 3.13 Na+/H+ exchanger isoform 1 -induced Cat B expression elicits an increase 
in autophagy in H9c2 cardiomyoblasts. A. Representative Western blot of LC3 protein 
expression of H9c2 cardiomyoblasts treated with Ang II in the presence and absence of 
EMD or CA-074Me for 24 hours (n=5). Immunoblotting was against LC3-I/II (14 and 16 
kDa). B. Quantification of relative levels of LC3-II protein expression (n=5). Results are 
expressed as a % of control (α-tubulin) ± %SEM. *p < 0.05 vs. control, # p < 0.05 vs. Ang 
II.   
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3.1.6.3 Measurement of Cat B in the Media 
Our previous findings indicate that stimulation of NHE1 using Ang II causes a loss 
of integrity of the lysosomes (Figure 3.12) and increases the number of autophagosomes 
(Figure 3.13). Moreover, activation of NHE1 has also shown to increase the secretion of 
Cat B into the extracellular spaces by mediating lysosomal redistribution to the cell 
peripheries (132, 136). Hence, we aimed to determine the protein levels of Cat B in the 
conditioned media obtained from H9c2 cardiomyoblasts treated with Ang II, with or 
without the NHE1 or Cat B inhibitors. Immunoblot analysis revealed that Cat B protein 
levels were significantly elevated following stimulation with Ang II (136.54    9.85% Ang 
II vs. 100% control; P<0.05) (Figure 3.14), an effect that was significantly regressed upon 
treatment with EMD (81.11  13.06% Ang II+EMD vs. 136.54    9.85% Ang II; P<0.05) 
(Figure 3.14). Similarly, Cat B protein expression in the media was significantly regressed 
when pre-treated with CA-074Me (94.32  12.96% Ang II+CA-074Me vs. 136.54    
9.85% Ang II; P<0.05) (Figure 3.14). It is to be noted that the immunoblot analysis revealed 
only the preform of Cat B in the media unlike that seen in the cell lysates. The presence of 
only the pro form of Cat B in the culture media can be explained by the presence of buffers 
in the media which maintain a neutral pH. Absence of optimal pH conditions can prevent 
the activation of pro Cat B and hence explain our inability to see the active form of the 
enzyme in the media (237). Moreover, it is also possible that the active form of Cat B is 
being degraded in the media as the half-life of Cat B is around 14 hours (60), which is less 
than our treatment condition of 24 hours. Our results demonstrate that stimulation of NHE1 
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with Ang II in H9c2 cardiomyoblasts induces an increase in Cat B protein expression in 
the extracellular compartment, which is inhibited by NHE1 or Cat B inhibition.  
A. 
 
B. 
 
Figure 3.14 Stimulation of the Na+/H+ exchanger isoform 1 elicits an increase in Cat 
B protein in the extracellular environment of H9c2 cardiomyoblasts. A. Representative 
Western blot of Cat B protein expression in the conditioned media of H9c2 
cardiomyoblasts treated with Ang II in the presence or absence of EMD or CA-074Me for 
24 hours (n=5). Immunoblotting was against Cat B (pro form at 37 kDa). B. Quantification 
of the relative levels of Cat B protein expression in the conditioned media (n=5). Results 
are expressed as a % of control (non-treated) ± %SEM. *p < 0.05 vs. control, # p < 0.05 
vs. Ang II. 
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3.1.6.4 Measurement of MMP-9 Gelatinolytic Activity and Protein Expression in the 
Conditioned Media 
3.1.6.4.1 Measurement of MMP-9 Gelatinolytic Activity in the Conditioned Media 
Previous reports have demonstrated that Cat B has the ability to activate pro-MMP-
9, which can result in further ECM degradation (218).  MMP-9 activity was also increased 
in CCL39 cells upon the stimulation of NHE1 with phenylephrine (222). Interestingly, Cat 
B and MMP-9 have been demonstrated to interact with NHE1 to promote ECM degradation 
in breast cancer (133). Hence, we aimed to determine the MMP-9 gelatinolytic activity in 
the conditioned media obtained from H9c2 cardiomyoblasts treated with Ang II, with or 
without the NHE1 or Cat B inhibitors. Gelatin zymography revealed that MMP-9 
gelatinolytic activity was significantly elevated following stimulation with 10 µM Ang II 
(134.37    5.61% Ang II vs. 100% control; P<0.05) (Figure 3.15), an effect that was 
significantly regressed upon stimulation with EMD (93.74  10.79% Ang II+EMD vs. 
134.37    5.61 % Ang II vs.; P<0.05) (Figure 3.15). Similarly, MMP-9 activity was 
significantly regressed when pre-treated with CA-074Me (85.24  13.17% Ang II+CA-
074Me vs. 134.37    5.61 % Ang II vs.; P<0.05) (Figure 3.15). Our results indicate that 
stimulation of NHE1 with Ang II in H9c2 cardiomyoblasts induces an increase in MMP-9 
gelatinolytic activity which is inhibited by NHE1 or Cat B inhibition.  
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A. 
 
B. 
 
Figure 3.15 Na+/H+ exchanger isoform 1 induced Cat B expression contributes to 
MMP-9 gelatinolytic activity in the extracellular environment of H9c2 
cardiomyoblasts. A. Representative zymogram  of MMP-9 gelatinolytic activity in 
conditioned media treated with Ang II, with or without EMD and CA-074Me for 24 hours 
(n=4). Bands were visualized at 92 kDa corresponding to MMP-9. B. Quantification of 
relative levels of MMP-9 bands (n=4). Results are expressed as % of control (non-treated) 
± %SEM. *p < 0.05 vs. control, # p < 0.05 vs. Ang II. 
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3.1.6.4.2 Measurement of MMP-9 Protein Expression in the Conditioned Media 
 
It had previously been reported that the levels of MMP-9 are increased in models 
of heart failure. Hence we looked at the MMP-9 protein quantity in the conditioned media. 
Our Immunoblot analysis revealed that the stimulation of NHE1 did not induce any 
changes in the MMP-9 protein levels conditioned media (Figure 3.16).  
A. 
 
B. 
 
Figure 3.16 Na+/H+ exchanger isoform 1 induced Cat B expression does not induce 
MMP-9 protein expression in the extracellular environment of H9c2 cardiomyoblasts. 
A. Representative Western blot of MMP-9 protein expression in conditioned media of 
H9c2 cells treated with Ang II, with or without EMD and CA-074Me for 24 hours (n=6). 
Immunoblotting was against MMP-9 (92 kDa). B. Quantification of relative levels of 
MMP-9 protein expression in the conditioned media (n=6). Results expressed as % of 
control (non-treated) ± %SEM.  
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3.1.7 Investigation of Signaling Pathways That Contribute Towards Cardiomyocyte 
Hypertrophy  
3.1.7.1 Measurement of OPN Protein Expression 
Previous reports have shown that OPN modulates Ang II induced cardiac fibrosis 
in mice hearts (242) Moreover, OPN has also been shown to be cause cardiomyocyte 
hypertrophy in cooperation with NHE1 (51, 52). Previous report have demonstrated that 
certain MMPs have a cleavage site on OPN (243). We have seen previously that Ang II 
causes a significant increase in MMP-9 activity (Figure 3.15). Hence, we wanted to 
determine whether this increase in MMP-9 activity had any effect on OPN protein 
expression. Our findings revealed that the OPN protein expression remained unchanged 
upon treatment with Ang II (Figure 3.17). 
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A. 
 
B. 
 
Figure 3.17 Na+/H+ exchanger isoform 1 induced Cat B expression does not induce 
OPN protein expression in H9c2 cardiomyoblasts. A. Representative Western blot of 
OPN protein expression in cell lysates of H9c2 cells treated with Ang II, with or without 
EMD and CA-074Me for 24 hours (n=3). Immunoblotting was against OPN (66 kDa) and 
α-tubulin (50 kDa). B. Quantification of relative levels of OPN protein expression (n=3). 
Results expressed as % of control (α-tubulin) ± %SEM. *p < 0.05 vs. control, # p < 0.05 
vs. Ang II.  
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3.1.8 Investigation of Apoptosis in the Cat B Induced Cardiomyocyte Hypertrophic 
Response; Measurement of Apoptotic Markers; Bcl2 and Bax mRNA 
Cat B and NHE1 have independently been shown to be involved in apoptosis (123, 
124) (244, 245). Moreover, previous report have demonstrated an increase in the apoptotic 
marker Bax mRNA and a decrease in the anti-apoptotic marker Bcl-2 mRNA in H9c2 
cardiomyoblasts treated with Ang II (216).  Hence, we wanted to see the effect of our 
treatment on the apoptotic markers. Our results revealed no change in the apoptotic markers 
which may be due to the different concentrations used in both studies (Figure 3.18, 3.19).  
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Figure 3.18 Na+/H+ exchanger isoform 1 induced Cat B expression does not induce 
Bax mRNA in H9c2 cardiomyoblasts. Quantification of BAX mRNA expression in H9c2 
cardiomyocytes normalized to β-actin (n=5). Results expressed as % of control (β-actin)  
%SEM.  
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Figure 3.19 Na+/H+ exchanger isoform 1 induced Cat B expression does not induce 
Bcl-2 mRNA in H9c2 cardiomyoblasts. Quantification of Bcl-2 mRNA expression in 
H9c2 cardiomyocytes normalized to β-actin (n=5). Results expressed as % of control (β-
actin)  %SEM. *p < 0.05 vs. control, # p < 0.05 vs. Ang II.  
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3.2 In vivo Studies to Investigate Cat B Protein Expression in Hearts from Transgenic 
Mice Overexpressing NHE1 (K-Line)  
 
3.2.1 Immunohistochemistry: Cat B Protein Expression in Transgenic Mice 
Overexpressing NHE1 (K-line)  
 
To confirm our in vitro studies, Cat B protein expression was examined in heart 
sections from wild type mice and mice overexpressing NHE1 (53). The results revealed 
increased Cat B staining in hearts (arrows indicate increased Cat B staining) from mice 
overexpressing NHE1 as compared to control hearts (Figure 3.20). Our results indicate that 
increased expression of NHE1 induces Cat B protein expression in vivo.  
  
 
Figure 3.20 In vivo immunohistochemical staining for Cat B in transgenic mice 
overexpressing NHE1 (K-line). Protein expression of Cat B in the myocardium of wild 
type mice and mice overexpressing NHE1 (K-line). Images were acquired through NIKON 
bright field microscope at a magnification of 40x. Scale bar=10 µm. 
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Chapter 4: DISCUSSION AND CONCLUSION 
Progression of the heart to failure is primarily caused due to significant remodeling 
of the myocardium. Remodeling occurs as a result of an imbalance between the synthesis 
and degradation of the ECM. This imbalance can occur as a result of increased proteolytic 
activities of proteases such as cathepsins and MMPs and decrease in the levels of TIMPs 
(77, 214). Cat B is active under conditions of low pH (86, 218, 237). A previous report has 
demonstrated that pericellular acidification redistributed the Cat B containing lysosomes 
to the cell surface and caused the secretion of Cat B into the extracellular compartment 
(86). An overactive NHE1, such as that which is seen in conditions of CH (50, 215, 246, 
247), contributes to pericellular acidification. Overactive NHE1 caused a drop in 
extracellular pH values, which was shown to activate Cat B in a breast cancer in vitro 
model (132). Once into the extracellular compartment, Cat B can degrade the ECM (68) 
and facilitate further ECM degradation by activating other proteases such as MMP-9 (217, 
218). MMP-9 activity has been shown to be increased in various models of heart failure 
(43, 49, 165, 219). Interestingly, Cat B and MMP-9 were shown to directly interact with 
NHE1 and cause ECM degradation (133). Whether Cat B participates in cardiac 
remodeling by mediating ECM degradation in cooperation with MMP-9 due to 
extracellular pH changes caused by the NHE1 remains unclear. Moreover, Cat B and NHE1 
have independently been shown to be involved in apoptosis (123, 124, 244, 245). Whether 
Cat B and NHE1 work in cooperation to induce apoptosis remains unknown.  
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 Our project aimed to delineate the role of Cat B in the NHE1 induced 
cardiomyocyte hypertrophic response. To investigate the effects of Cat B in the NHE1 
induced cardiomyocyte hypertrophic response we used both an in vitro model as well as 
an in vivo model. Ang II was used to stimulate NHE1 activity in H9c2 cardiomyoblasts. 
Changes in the Cat B gene and protein expression as well as activity were analyzed in the 
presence and absence of Cat B or NHE1 inhibitor. We also looked at the protein levels of 
Cat B in transgenic mice harboring the active form of NHE1. Furthermore, we also looked 
at the effects of NHE1 induced cardiomyocyte hypertrophy on activation of autophagy and 
the extracellular Cat B protein expression and MMP-9 activity. We also assessed the 
cardiomyocyte hypertrophic response by measuring the well-established cardiomyocyte 
hypertrophic markers ANP mRNA, cell area and protein content. Our findings have several 
implications: 
 
4.1 Ang II induces an increase in NHE1 activity without an increase in its protein 
expression 
Previous reports have demonstrated that NHE1 activity increases upon stimulation with 
Ang II in ventricular myocytes (227). Previous reports have suggested that the Ang II 
stimulates the activity of NHE1 by the activation of Gαq protein coupled receptors (section 
1.5.3.2). Activation of Gαq signaling then activates downstream signaling cascade (Figure 
1.4). Ang II, acting via the AT1 receptor (Gαq), induces an increase in intracellular calcium 
that then interacts with calmodulin (CaM). The Ca2+/CaM complex directly or indirectly 
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activates NHE1 and phosphorylates calmodulin kinase II (CaMKII), which then regulates 
the NHE1 activity (248). In our study, the NHE1 activity assay revealed that the NHE1 
activity was significantly increased upon stimulation with 100 nM Ang II for 18 hours and 
this effect was significantly regressed by using EMD, confirming previous reports (51, 52) 
(Figure 3.1). Based on our findings and previous reports, we used Ang II to induce NHE1 
activity in our study in H9c2 cardiomyoblasts. 
In order to assess if stimulation with Ang II also induces NHE1 protein expression, we 
treated the H9c2 cells with 10 µM Ang II for 24 hours in the presence and absence of Cat 
B or NHE1 inhibition. Immunoblot analysis revealed that Ang II or the inhibition of Cat B 
did not have any changes in the NHE1 protein levels upon stimulation with Ang II in H9c2 
cardiomyoblasts (Figure 3.2). This is in accordance with what has been previously 
reported. A study demonstrated that MDCK cell treated with 1 nM Ang II did not stimulate 
an increase in the protein expression of NHE1 whereas, the treatment was sufficient to 
induce an increase in NHE1 activity (248).  
 
4.2 Stimulation of NHE1 Induces the Expression of Cat B 
Cat B and NHE1 have independently been shown to mediate CH (36, 53, 91, 214). 
Moreover, the activation NHE1 has been shown to activate Cat B in a breast cancer model 
(132). Hence, we investigated the effect of overactive NHE1 (stimulated using Ang II) on 
the Cat B protein expression in H9c2 cardiomyoblasts. Immunoblot analysis revealed that 
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Cat B protein expression in its pro and active forms were significantly increased in H9c2 
cardiomyoblasts upon stimulation with 10 µM Ang II for 24 hours (Figure 3.3).  
The pro region of the pro Cat B enzyme is cleaved off to liberate the mature or active 
form of Cat B which is of 30 kDa. The pro Cat B can be converted into active Cat B by 
exposure to low pH, or to Cat D (aspartic protease) (237). Pro Cat B can also convert to its 
active form by self-cleavage (74-76). Furthermore, the 30 kDa active form can be further 
processed by cleavage of its dipeptide bonds and liberation of its heavy chain (25 kDa) and 
a light chain (5 kDa). The heavy and light chains forms are linked together cysteine–
cysteine bonds (60). It is to be noted that Cat B pro form is indicated to be enzymatically 
inactive and requires an acidic pH to become active. Although it shows maximum activity 
at an acidic pH, it has been found that Cat B retains significant proteolytic activity at neutral 
pH as well (88).  
Apart from investigating the concentration of Ang II at which it induces maximum 
Cat B expression we also wanted to know the time point for the same. For this we used a 
concentration of 10 µM Ang II (Figure 3.3) at different time points (section 2.2 (c)). 
Immunoblot analysis revealed that Cat B protein expression was maximally increased at 
24 hours (Figure 3.4). This is in accordance with a recent study, where they induced Cat B 
protein expression in H9c2 cardiomyoblasts using Ang II at a 24 hour time point (216). 
Hence, for our study we used a concentration of 10 µM Ang II for 24 hours to induce Cat 
B protein expression. The H9c2 cell line shows a similar hypertrophic response as the 
primary cardiomyoblasts and hence is used as a model for in vitro study of CH (225).  
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Furthermore, our study demonstrated that the Cat B mRNA expression was 
significantly increased in H9c2 cardiomyoblasts upon stimulation with 10 µM Ang II for 
24 hours (Figure 3.6). This increase in Cat B protein and gene expression was regressed 
upon inhibition of NHE1 or Cat B (Figure 3.5 and 3.6). A study done on bone marrow 
derived macrophages demonstrated that CA-074Me has the ability to affect transcription 
factor NFATc1 through down regulation of c-FOS. Auto-amplification of NFATc1 is 
necessary for the transcription of genes such as those of cathepsins. This study 
demonstrated that CA-074Me was able to inhibit the NFATc1 mRNA via inhibiting c-FOS 
resulting in the inhibition of transcription. This study might explain the inhibition of Cat B 
mRNA upon using CA-074Me in our model (249).   
To confirm our in vitro studies, we investigated Cat B protein expression in an in 
vivo model. Immunohistochemical analysis done on heart sections from wild type mice and 
mice overexpressing NHE1 (53) revealed increased Cat B staining in hearts from mice 
overexpressing NHE1 as compared to control hearts (Figure 3.20). Our results indicate that 
the activity and expression of NHE1 induces Cat B protein levels in vitro and in vivo 
respectively (Figure 3.5 and 3.20). These findings are in accordance with Wu et al’s recent 
findings that demonstrated an increase in Cat B upon stimulation with Ang II (216). 
Moreover, Wu et al demonstrated that Cat B deficiency attenuated cardiac remodeling in 
response to pressure overload (216). Whether the effects seen in Wu et al’s study were as 
a result of activation of NHE1 have not been investigated. Previous reports have showed 
that pressure overload can lead to the activation of NHE1 (228). The results obtained in 
our study from NHE1 transgenic mice and the inhibition of NHE1 in H9c2 cardiomyoblasts 
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show for the first time that Ang II stimulation of Cat B is mediated by NHE1. Hence, 
indirect inhibition of NHE1 by inhibiting Cat B may prove to be a useful strategy to prevent 
CH. 
Apart from Cat B, various other forms of cathepsins have been suggested to be essential 
for developing a hypertrophic phenotype. A previous study showed that in cultured 
neonatal rat cardiomyocytes the gene and protein levels of Cat S, B, and L were upregulated 
(36). Similarly, Cat S has been shown to be increased in the failing rat myocardium in 
association with hypertension (36). Levels of Cat S were also increased in hearts extracted 
from patients with heart failure (36). Loss of Cat L promoted CH upon phenylephrine-
induced CH in vitro (131). Another study reported that MI induced by left coronary artery 
ligation in wild-type rats caused rapid Cat L activation in the myocardium and its 
deficiency contributed to diminished function and adverse remodeling late post-MI. 
Moreover, Cat S seems to play a role in cardiac maintenance as well since its deletion 
exacerbated Ang II-induced cardiac inflammation (101).  Although many forms of 
cathepsin have been suggested to contribute to the hypertrophic phenotype, in our report 
we focused on Cat B, which is activated by an acidic pH (86, 132). Whether the various 
forms of cathepsins are simultaneous up regulated in a model of hypertrophy or the 
interplay between the various forms of cathepsins remains unknown. Further experiments 
are needed in order to find out the role of other forms of cathepsins that are implicated in 
CH such as Cat S, K and L. 
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4.3 Stimulation of NHE1 Induces Cat B Mediated Cardiomyocyte Hypertrophy  
Despite numerous reports that indicate the involvement of Cat B in the hypertrophic 
response, the exact mechanism by which it induces cardiomyopathy remains unknown. 
NHE1 has also been shown to mediate CH (36, 53, 91, 214, 250, 251). Whether active 
NHE1 contributes to the Cat B mediated hypertrophic response I still not known. In vitro, 
pharmacological Cat B inhibition using CA-074Me suppressed the cardiomyocytes 
hypertrophy by inhibiting the ASK1/JNK pathway (216). In vivo Cat B deficiency 
attenuated the cardiac remodeling process in response to pressure overload (216). 
Similarly, Cat B inhibition using CA-074Me significantly attenuated cardiac dysfunction, 
reduced cardiomyocyte size and cardiac fibrosis in vivo (96). In patients with dilated 
cardiomyopathy, Cat B has been demonstrated to be elevated (91).  
Investigation of the cardiomyocyte hypertrophic cascade revealed a significant increase 
in all three cardiomyocyte hypertrophic markers (Figure 3.9, 3.10, 3.11) confirming 
previous reports, which have demonstrated that overactive NHE1 induces cardiomyocyte 
hypertrophy (54, 55, 252). This increase was significantly regressed upon inhibition of 
NHE1 or Cat B (Figure 3.9, 3.10, 3.11). These findings are in accordance with Wu et al’s 
recent findings that demonstrated a decrease in the cardiomyocyte hypertrophy upon 
inhibition of Cat B using CA-074Me (216). Our findings reveal for the first time that Cat 
B expression contributes to the hypertrophic response in cardiomyoblasts and that blockage 
of this effect prevents the NHE1 induced hypertrophic response. The results from our study 
provide evidence that NHE1 induced cardiomyocyte hypertrophic response is mediated by 
Cat B. Hence, inhibition of Cat B may prove to be useful in regressing CH.   
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4.4 Stimulation of NHE1 Causes the Dispersion of Lysosomes Which is Protected by 
the Inhibition of Cat B  
Hydrogen ions (H+) or protons are important for the regulation of many 
physiological process like DNA synthesis, cell cycle, cell volume, cell growth, and cell 
proliferation. The levels of proton are controlled by exchangers present on the cell 
membranes such as the NHEs, Na+-dependent and -independent HCO3-/Cl− exchangers and 
the H+/lactate co transporter (174). It has been demonstrated that lysosomes were 
redistributed to the cell periphery upon a drop in the extracellular pH values caused by an 
overactive NHE1 (132, 133). (86, 134, 135). This can subsequently cause the secretion of 
lysosomal contents into the ECM as it has been shown for Cat B which is primarily present 
within the lysosomes (86). Moreover, acidic extracellular pH caused the redistribution of 
the lysosome to the cell periphery which paralleled cathepsin B secretion. Interestingly this 
effect was blocked with several broad and specific NHE inhibitors (136). Similarly, in our 
study we demonstrated that H9c2 cardiomyoblasts stimulated with Ang II showed more 
dispersed lysosomal vesicles as compared to control (Figure 3.12). This effects seemed to 
be protected upon inhibition of the NHE1 or Cat B, where the H9c2 cardiomyoblasts 
showed a more intact structure of the lysosomes (Figure 3.12). The loss of integrity of the 
lysosomes can cause the release of the Cat B proteases into the cytosol or into the 
extracellular compartment (86).   
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4.5 Stimulation of NHE1 Causes the Activation of Autophagy Which is regressed by 
the Inhibition of Cat B 
The autophagy–lysosomal system and the ubiquitin–proteasome system (UPS) are 
responsible for majority of the protein degradation in eukaryotic cells (128). In the 
cardiovascular system there is a fine balance between the two systems to maintain 
homeostasis of proteins and organelles (129). The UPS targets small and short lived protein 
by tagging them with ubiquitin (129). In contrast, the autophagy–lysosomal pathway 
targets long-lived bulky proteins that are defected or damaged under stress (130). Impaired 
or dysregulated protein degradation in the heart has recently been recognized as a potential 
major contributor to cardiac disease. Cathepsins an important lysosomal protein–
processing enzyme that play an important role in maintaining the autophagy- lysosomal 
pathway activated in response to stress (131). The final step of the autophagy–lysosomal 
pathway is the fusion of an autophagosome with a functioning lysosome, and an imbalance 
of protein homeostasis by dysfunction of this system may lead to pathological hypertrophy 
and dysfunction. It has been reported that lysosomal proteases such as cathepsins play a 
major role in cardiac protein turnover, but the mechanism is not well understood. 
Moreover, NHE1 mediated changes in pH has also been shown to promote autophagy in 
neurons (240). Hence, we aimed to determine the levels of LC3-II protein. Our results 
revealed that LC3-II protein expression was significantly elevated following stimulation 
with Ang II (Figure 3.13) and this effect that was significantly regressed upon treatment 
with EMD or CA-074Me (Figure 3.13). Our results demonstrate that stimulation of NHE1 
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induces a significant increase in autophagy and this is regressed by inhibition of NHE1 and 
Cat B. 
 
4.6 Stimulation of NHE1 Induces an Increase in Cat B Protein in the Extracellular 
Compartment 
Decreased extracellular pH values can cause increased redistribution of lysosomes to 
the cell surface (86) which may be accompanied by the fusion of an autophagosome with 
a functioning lysosome (131). This can subsequently cause the secretion of Cat B, into the 
ECM (86). Our previous findings indicate that stimulation of NHE1 using Ang II causes 
increased dispersion of lysosomes (Figure 3.12) and increases the number of 
autophagosomes (Figure 3.13). Hence, we wanted to investigate the Cat B protein aimed 
to determine the protein levels of Cat B in the conditioned media obtained from H9c2 
cardiomyoblasts with an overactive NHE1. Our results demonstrate that pro-Cat B protein 
levels were significantly elevated in the extracellular compartment (Figure 3.14). This 
effect was significantly regressed by inhibition of NHE1 or Cat B (Figure 3.14). 
Surprisingly, only pro Cat B levels were detected in the extracellular compartment.  It is to 
be noted that Cat B pro form is indicated to be enzymatically inactive and requires an acidic 
pH to become active. Our in vitro model contain buffers in the culture media to maintain 
the pH of the cardiomyoblasts. Due to the presence of the buffers in our culture media we 
do no encounter an acidic extracellular environment which is required for Cat B activation. 
However, it has been reported that Cat B can retain significant proteolytic activity at neutral 
pH as well (88), and as such is capable of activating pro MMP-9 in the extracellular 
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environment (218). Once into the extracellular compartment, Cat B can cause further ECM 
degradation by activating MMP-9 (217, 218).  
 
4.7 Increase in Cat B Protein in the Extracellular Compartment Induces an Increase 
in MMP-9 Activity 
A recent study has demonstrated that acidic extracellular pH values increase MMP-9 
and Cat B secretion (133). Cat B has also been shown to mediate the pH dependent 
activation of pro-MMP-9 (218). Moreover, Cat B and MMP-9 were shown to directly 
interact with NHE1 and cause ECM degradation (133). Hence, we aimed to determine the 
MMP-9 gelatinolytic activity in the conditioned media obtained from H9c2 
cardiomyoblasts with overactive NHE1. Gelatin zymography revealed that MMP-9 
gelatinolytic activity was significantly elevated following stimulation of NHE1 with Ang 
II (Figure 3.15). This effect was significantly regressed upon inhibition of NHE1 or Cat B 
(Figure 3.15). In our study, the gelatin zymograms were able to detect MMP-9 at 92 kDa 
only, which is in accordance with what has been observed in earlier studies (218, 253). The 
band corresponding to 92 kDa is mostly described as the inactive form of MMP-9. 
However, certain protein substrates, such as collagen IV and glycoproteins, have been 
shown to cause conformational changes within the MMP-9 structure that result in the 
exposure of the active site without cleavage of the pro-peptides (254, 255). MMP-9 activity 
has been shown to be increased in various models of heart failure (43, 219). Hence, 
activation of MMP-9 can result in ECM degradation, which can contribute further towards 
cardiomyocyte hypertrophy (43, 165, 219). We also looked at the MMP-9 protein 
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expression in the extracellular compartment. However, Immunoblot analysis revealed no 
change in MMP-9 protein expression in the conditioned media (Figure 3.16). It is to be 
noted that zymography is known to be a much more sensitive method than Western blotting 
as it is able to detect small amounts of activity as well. This might explain why our 
zymography experiments revealed changes in MMP-9 activity, whereas the immunoblot 
analysis did not. 
 
4.8 NHE1 Induced Increase in Cat B Expression does not Activate Apoptosis 
Cardiomyocyte apoptosis is commonly seen in the progression of heart failure (113, 
114). Apoptosis is a cell death mechanism primarily regulated by caspases, a family of 14 
cysteine proteases that cleave their substrates specifically at an Asp residue (115). Both 
extrinsic (death receptor-mediated) and intrinsic (mitochondrial- mediated) apoptotic 
pathways activate caspases which subsequently degrade numerous polypeptides in the cell 
including major structural elements, DNA repair machinery, and protein kinases (115). In 
cardiomyocytes, the predominant apoptotic pathway is intrinsic (116), primarily through 
Bcl-2 protein involvement, and procaspase activation (117, 118).  
Cat B and NHE1 have independently been shown to be involved in apoptosis (123, 
124) (244, 245). Inhibition of NHE1 activity via the specific inhibitor cariporide resulted 
in decreased apoptosis in isolated cardiomyocytes (256). Another study reported that in an 
ischemic rat model, the NHE1 inhibitor cariporide reduced apoptosis and this was 
associated with a significantly higher ratio of (antiapoptotic) Bcl-2 to (pro-apoptotic) Bax 
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genes (250, 257, 258). NHE1 has been implicated in NHE1 induced apoptosis in the 
myocardium (244, 245). Previous studies have demonstrated that cathepsins are essential 
for cardiomyocyte apoptosis (97) (123, 124). An absence of Cat B and L has been shown 
to induce neuronal loss and brain atrophy (125). Cat B has also been shown to mediate 
caspase-independent cell death in non-small cell lung cancer cells (126). Once Cat B is 
released from the lysosomes into the cytoplasm it may activate or enhance apoptotic 
pathways (126). Moreover, the antiapoptotic molecules Bcl-2, Bcl-xL, Mcl-1, and XLAP 
(X-chromosome linked inhibitor of apoptosis) are targeted by the lysosomal Cat B and L 
in several human cancer cell lines (127). Recently, Wu et al have demonstrated an increase 
in the apoptotic marker Bax mRNA and a decrease in the anti-apoptotic marker Bcl-2 
mRNA in H9c2 cardiomyoblasts treated with Ang II (216).  Hence, we wanted to see the 
effect of our treatment on the apoptotic markers, Bcl-2 and Bax mRNA. Our results 
revealed no changes in Bax and Bcl-2 mRNA (Figure 3.18 and 3.19). However, recently 
Wu et al demonstrated an increase in Bax protein expression and a decrease in Bcl-2 
protein expression in H9c2 cardiomyoblasts upon stimulation with Ang II (216). The 
differences in our study and Wu et al’s may be due to the different concentrations of Ang 
II used in both studies (216). Based on our findings, we speculate that the cardiomyocytes 
might be undergoing a biphasic response in relation to autophagy and apoptosis, where one 
pathway may dominate the other one. Further studies are needed to better understand the 
crosstalk between autophagy and apoptosis in NHE1 induced CH. Our study showed that 
the Cat B mediated hypertrophic response induced the activation of the autophagic pathway 
alone without any activation in apoptosis.   
107 
 
CONCLUSION 
Our study demonstrated for the first time that stimulation of NHE1 caused an 
increase in the Cat B protein and gene expression. This increase was regressed upon 
inhibition of NHE1 or Cat B (Figure 4.1). Moreover, cardiomyoblasts expressing active 
NHE1 significantly increased the cardiomyocyte hypertrophic markers (Figure 4.1). The 
inhibition of NHE1 or Cat B regressed this hypertrophic response indicating an important 
role of NHE1 in the Cat B induced cardiomyocyte hypertrophic pathway. Furthermore, 
stimulation of NHE1 caused the disruption of the lysosomes within the H9c2 
cardiomyoblasts and also induced an increase in the LC3 protein levels. This indicates that 
the autophagy-lysosomal pathway plays a role in mediating the Cat B induced 
cardiomyocyte hypertrophy. The activation of the autophagy-lysosomal pathway caused 
the secretion of Cat B into the extracellular compartment where it activated pro-MMP-9. 
These effects seemed to be regressed upon inhibition of NHE1 or Cat B (Figure 4.1).  The 
extent to which the conclusions of the present work may be applicable to native 
cardiomyoblasts and in vivo heart will require further studies using appropriate animal 
models. This shall confirm the results obtained in the present study.  
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Figure 4.1 Cathepsin B and MMP-9 mediate NHE1-induced cardiomyocyte-
hypertrophic response. The stimulation of NHE1 through Ang II causes an up regulation 
in Cat B protein and gene expression intracellularly. Cat B then moves into the extracellular 
compartment and activates MMP-9, resulting in the NHE1-induced cardiomyocyte 
hypertrophic response. NHE1, Na+/H+ Exchanger 1; Cat B, cathepsin B; MMP-9, matrix 
metalloproteinase-9 
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Chapter 6: FUTURE DIRECTIONS 
5.1 Activation of NHE1 Causes ECM Degradation That is Mediated through Cat B 
and MMP-9 
ECM consists of protein such as collagen and elastin which are vital for maintaining 
the integrity of the ECM network. Various isoforms of cathepsins and MMPs are able to 
degrade many ECM components such as fibrin, collagen and its isoforms, elastin. It has 
been reported that the elastolytic and collagenolytic activities in the LV myocardium of 
hypertensive heart failure rats were increased significantly in response to increased 
expression of in cathepsin S, K, L and B expression (36). Moreover, the elastolytic activity 
was significantly decreased upon treatment with E64, a broad spectrum cathepsin inhibitor 
and the collagenolytic activity was significantly decreased upon using GM6001, a MMP-
2/9 inhibitor (36).  Furthermore, NHE1 has been shown to directly interact with Cat B and 
MMP-9 and cause ECM degradation in a breast cancer cell line (133). The results of our 
study demonstrate that the protein levels of Cat B and MMP-9 activity was increased in 
the media. However, we did not investigate the effect of increased Cat B expression and 
MMP-9 activity upon their ECM substrates like elastin, and collagen. The logical next step 
would be to investigate the effect of overexpression of Cat B and MMP-9 in an in vitro and 
in vivo model upon elastin and collagen. In an in vitro model, this could be done by running 
elastolytic and collagenolytic assay in the absence or presence of Cat B or MMP-9 
inhibitors. In an in vivo model, we can analyze the elastin and collagen compositions by 
performing IHC analysis and comparing with control hearts. For this we could utilize 
transgenic mice overexpressing the NHE1 (K-line). The results from these experiments 
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would provide us with conclusive evidence regarding ECM degradation due to NHE1 
induced CH. This would provide conclusive evidence that the NHE1 induced increase in 
Cat B and in turn increase in MMP-9 activity is in fact mediating ECM degradation that 
contributes towards cardiomyocyte or CH.  
  
5.2 Cat B Induced Cardiomyocyte Hypertrophy is Mediated through NHE1 and NF-
kB  
Nuclear factor-kappa B (NF-κB) is a ubiquitously expressed cellular transcription 
factor. NF-κB can be activated by various cytokines, such as tumor necrosis factor-alpha 
(TNF-α). Phosphorylation and degradation of I-κB alpha unit is necessary for its activation. 
NF-κB has been implicated in the regulation of cell survival, inflammation and immune 
cell maturation in cardiac myocytes. Several clinical studies have found a strong link 
between NF-κB activation and heart failure. It is suggested that NF-κB promotes heart 
failure by the activation of cytokines such as TNF-α and interleukin-1β (IL-1β). It has been 
demonstrated that failed human hearts contain activated forms of NF-κB, whereas normal 
hearts do not (259, 260). Moreover, it has been shown that polymorphisms in the promoter 
of the NF-κB gene causes the up regulation of NF-κB . Up regulation of NF-κB has been 
identified as a risk factor for DCM (261). A study of patients that received left ventricular 
assist devices demonstrated that reverse remodeling and enhanced function was associated 
with a decline in cardiac NF-κB activity (262). In cultured cardiac myocytes, hypertrophic 
agonists that activate Gαq coupled receptors, such as Ang II, ET-1, and phenylephrine, all 
promote nuclear translocation and transcriptional activity of NF-κB (263, 264). In addition, 
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NF-κB activity is required for the hypertrophic phenotype induced by these agonists and 
for the increased expression of atrial natriuretic factor (ANF) in postnatal ventricular cells, 
an important marker of fetal gene activation and pathological remodeling. In vivo studies 
have confirmed in vitro results, in that cardiac-specific expression of a mutant NF-κB IκBα 
subunit super-repressor attenuates the hypertrophic cardiac phenotype induced by Ang II 
and isoproterenol infusion, or low-grade aortic banding; as well as, the induction of a subset 
of fetal cardiac genes (265, 266). Furthermore, the NF-κB p50 subunit deficient mice 
display reduced CH following MI or during TNFα-induced cardiomyopathy (267, 268).  
Interestingly, NHE blockade inhibits IL-1β and NF-κB in immunostimulated 
endothelial cells (269). Moreover, NF-κB has been shown to upregulate Cat B expression 
in H9c2 cardiomyoblasts (238). A potential NF-κB binding site could be identified on the 
gene promoter region of Cat B. It was also demonstrated that pretreatment of HeLa cells 
with specific NF-κB inhibitors abrogated the induction of Cat B expression (238). Up 
regulation of Cat B by NF-κB, followed by its secretion into the extracellular environment 
was seen in another cancer cell line (270). It was also demonstrated that the down-
regulation of the NF-κB p65 subunit led to a reduction in Cat B expression in the same cell 
line (270). Taken together, it is clear that NF-κB is involved in CH and heart failure, but 
further studies are required to establish whether it function in cooperation with NHE1 or 
Cat B to promote CH or not. In order to further investigate the signaling pathways, isolated 
cells in vitro and lineage-specific knockouts should now be carried out to define the 
transcriptional targets and function of NF-κB in cardiomyocytes. For an in vitro model, 
H9c2 cell lines treated with prohypertrophic agents such as Ang II could be used to 
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stimulate NHE1. After treatment and incubation for a specified time, the nuclear fraction 
of H9c2 cells could be examined for NF-kB levels and NF-k B activity. Use of NF-kB 
inhibitors can be used to further tweeze out the signaling pathway and to determine whether 
NF-kB is in fact involved in the NHE1/CatB induced cardiomyocyte hypertrophic 
response.  
 
5.3 Cat B Induced Cardiomyocyte Hypertrophy is Mediated through NHE1 and 
CD44 
The CD44 is a cell-surface glycoprotein involved in cell–cell interactions, cell adhesion 
and migration. The CD44 is responsible for transducing intracellular signals in the 
myocardial cells. CD44 interact with various components of the ECM such as hyaluronan 
(HA), collagen, laminin, fibronectin and OPN (56). In MI hearts, CD44 is upregulated in 
fibroblasts, leukocytes, and endothelial cells (58). CD44 deficient mice subjected to MI 
show increased myocardial infiltration by leukocytes and expression of proinflammatory 
cytokines, followed by a decrease in fibroblast infiltration and fibrosis and enhanced 
dilative cardiac remodeling (58). Interestingly, a study demonstrated that the binding of 
HA to CD44 activates NHE1 activity which, in turn, creates an acidic extracellular matrix 
environment. The acidic extracellular environment leads Cat B activation. Increased Cat B 
activation causes degradation of the ECM which results in tumor progression. Moreover, 
inhibition of NHE1 activity by amiloride blocked NHE1 activity, reduced the acidic 
environment, and inhibited Cat B activation, and tumor cell invasion. Similar effects were 
seen upon downregulation of CD44 by using short interfering RNA (132). Therefore, it 
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would be interesting to investigate the effects of CD44 up regulation and inhibition on 
cardiomyocyte hypertrophic response. The results could further tweeze out the signaling 
pathways that lead to ECM remodeling in the NHE1/Cat B induced cardiomyocyte 
hypertrophy.  
 
5.4 Cat B Induced Cardiomyocyte Hypertrophy is Mediated through NHE1 and IL-
1β 
IL-1β signaling is thought to be a vital mediator in the pathogenesis of cardiac 
remodeling. It has been demonstrated that the exogenous administration, in vivo and in 
vitro, has led to structural remodeling with reduced cardiac function (271). It has been 
suggested that IL-1β may induce systolic dysfunction in patients with heart failure, further 
supporting a negative role for this cytokine in heart disease (272, 273). Another study 
demonstrated a significant increase in the serum levels of IL-1β in rats after left anterior 
descending coronary artery ligation procedure compared with the sham control rats (96). 
In post-MI clinical trials, administration of IL-1 antagonist reduced adverse remodeling 
and improved cardiac function (274). Interestingly, IL-1β also increased the amounts of 
Cat K, B, and L mRNAs in cultured neonatal rat cardiomyocytes (36). In addition, previous 
studies have shown that Cat B and IL-1β work together to promote cardiac remodeling 
following MI in mice. (275). Evidence also indicates that NHEs are activated in response 
to IL-1β (276). Taken together, the mentioned reports suggests that IL-1β might be 
mediating the CH effects seen upon up regulation of NHE1 or Cat B. We hypothesize that 
increase in IL-1β levels cause an increase in NHE1 expression or activity which leads to 
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the increase in Cat B leading to CH.  The hypothesis could be tested out in an in vitro 
model, by exposing the cardiomyocytes to IL-1β and measuring the changes in NHE1 
activity and Cat B protein expression to a control non treated group. This would confirm 
whether IL-1β is in fact involved in the NHE1/Cat B induced cardiomyocyte hypertrophic 
cascade or not.  
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